Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
35 "Eui Kyu Chie"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Hye In Lee, Bum-Sup Jang, Ji Hyun Chang, Eunji Kim, Tae Hoon Lee, Jeong Hwan Park, Eui Kyu Chie
Received June 2, 2024  Accepted December 13, 2024  Published online December 16, 2024  
DOI: https://doi.org/10.4143/crt.2024.521    [Accepted]
AbstractAbstract PDF
Purpose
This study aimed to investigate the dynamic changes in the microbiome of patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT), focusing on the relationship between the microbiome and response to nCRT.
Materials and Methods
We conducted a longitudinal study involving 103 samples from 26 patients with LARC. Samples were collected from both the tumor and normal rectal tissues before and after nCRT. Diversity, taxonomic, and network analyses were performed to compare the microbiome profiles across different tissue types, pre- and post-nCRT time-points, and nCRT responses.
Results
Between the tumor and normal tissue samples, no differences in microbial diversity and composition were observed. However, when pre- and post-nCRT samples were compared, there was a significant decrease in diversity, along with notable changes in composition. Non-responders exhibited more extensive changes in their microbiome composition during nCRT, characterized by an increase in pathogenic microbes. Meanwhile, responders had relatively stable microbiome communities with more enriched butyrate-producing bacteria. Network analysis revealed distinct patterns of microbial interactions between responders and non-responders, where butyrate-producing bacteria formed strong networks in responders, while opportunistic pathogens formed strong networks in non-responders. A Bayesian network model for predicting the nCRT response was established, with butyrate-producing bacteria playing a major predictive role.
Conclusion
Our study demonstrated a significant association between the microbiome and nCRT response in LARC patients, leading to the development of a microbiome-based response prediction model. These findings suggest potential applications of microbiome signatures for predicting and optimizing nCRT treatment in LARC patients.
  • 286 View
  • 20 Download
Close layer
Low‒Dose Cyclophosphamide Enhances the Tumoricidal Effects of 5-Day Spacing Stereotactic Ablative Radiotherapy by Boosting Antitumor Immunity
Hyunkyung Kim, Seok-Joo Chun, Sojung Sun, Haeun Cho, Tae-Jin Kim, Yoon-Jin Lee, Eui Kyu Chie, Kwangmo Yang, Mi-Sook Kim
Received August 21, 2024  Accepted November 7, 2024  Published online November 8, 2024  
DOI: https://doi.org/10.4143/crt.2024.807    [Accepted]
AbstractAbstract PDF
Purpose
To investigate the potential role of low‒dose cyclophosphamide (Cy) as a radiosensitizer by evaluating its impact on the immune response and the abscopal effect of stereotactic ablative radiotherapy (SABR) through preclinical models.
Materials and Methods
CT26 tumors (immunologically hot) and 4T1 tumors (immunologically cold), grown in immunocompetent BALB/c and immunodeficient BALB/c‒nude mice, were irradiated with 20 Gy in two fractions with 5‒day spacing followed by intraperitoneal injections of 9 mg/kg Cy every 3 days. Immunological changes in CT26 tumors caused by the treatments were assessed using flow cytometry. Changes in the expression of HIF‒1α in tumors were also assessed. Splenocytes and bone marrow‒derived dendritic cells (DCs) were exposed to various concentrations of Cy to assess T cell proliferation and DC differentiation.
Results
The combination of Cy with RT (RT+Cy) significantly suppressed tumor growth compared to RT alone in immunocompetent mice, while that effect was not observed in immunodeficient mice. Additionally, RT+Cy effectively induced abscopal effects in hot and cold tumors, with increased CD8+ T cells in blood and tumors. Significantly higher expression levels of Granzyme B, IFN‒γ, and TNF‒α were observed in RT+Cy group compared to the RT alone group. In vitro data indicated that low‒dose Cy promotes DC differentiation. Low‒dose Cy suppressed the radiation‒induced upregulation of HIF‒1α in the tumors.
Conclusion
Low‒dose Cy enhances tumoricidal effects of 5‒day spacing high‒dose RT by increasing anti-tumor immune responses.
  • 422 View
  • 43 Download
Close layer
Gastrointestinal cancer
Integrating Deep Learning–Based Dose Distribution Prediction with Bayesian Networks for Decision Support in Radiotherapy for Upper Gastrointestinal Cancer
Dong-Yun Kim, Bum-Sup Jang, Eunji Kim, Eui Kyu Chie
Cancer Res Treat. 2025;57(1):186-197.   Published online August 2, 2024
DOI: https://doi.org/10.4143/crt.2024.333
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Selecting the better techniques to harbor optimal motion management, either a stereotactic linear accelerator delivery using TrueBeam (TBX) or magnetic resonance–guided gated delivery using MRIdian (MRG), is time-consuming and costly. To address this challenge, we aimed to develop a decision-supporting algorithm based on a combination of deep learning-generated dose distributions and clinical data.
Materials and Methods
We retrospectively analyzed 65 patients with liver or pancreatic cancer who underwent both TBX and MRG simulations and planning process. We trained three-dimensional U-Net deep learning models to predict dose distributions and generated dose volume histograms (DVHs) for each system. We integrated predicted DVH metrics into a Bayesian network (BN) model incorporating clinical data.
Results
The MRG prediction model outperformed the TBX model, demonstrating statistically significant superiorities in predicting normalized dose to the planning target volume (PTV) and liver. We developed a final BN prediction model integrating the predictive DVH metrics with patient factors like age, PTV size, and tumor location. This BN model an area under the receiver operating characteristic curve index of 83.56%. The decision tree derived from the BN model showed that the tumor location (abutting vs. apart of PTV to hollow viscus organs) was the most important factor to determine TBX or MRG. It provided a potential framework for selecting the optimal radiation therapy (RT) system based on individual patient characteristics.
Conclusion
We demonstrated a decision-supporting algorithm for selecting optimal RT plans in upper gastrointestinal cancers, incorporating both deep learning-based dose prediction and BN-based treatment selection. This approach might streamline the decision-making process, saving resources and improving treatment outcomes for patients undergoing RT.
  • 868 View
  • 70 Download
Close layer
Prognostic Evaluation and Survival Prediction for Combined Hepatocellular-Cholangiocarcinoma Following Hepatectomy
Seok-Joo Chun, Yu Jung Jung, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Kyoung Bun Lee, Hyun-Cheol Kang, Eui Kyu Chie, Kyung Su Kim
Cancer Res Treat. 2025;57(1):229-239.   Published online July 3, 2024
DOI: https://doi.org/10.4143/crt.2024.176
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to assess prognostic factors associated with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to predict 5-year survival based on these factors.
Materials and Methods
Patients who underwent definitive hepatectomy from 2006 to 2022 at a single institution was retrospectively analyzed. Inclusion criteria involved a pathologically confirmed diagnosis of cHCC-CCA.
Results
A total of 80 patients with diagnosed cHCC-CCA were included in the analysis. The median progression-free survival was 15.6 months, while distant metastasis-free survival (DMFS), hepatic progression-free survival, and overall survival (OS) were 50.8, 21.5, and 85.1 months, respectively. In 52 cases of recurrence, intrahepatic recurrence was the most common initial recurrence (34/52), with distant metastasis in 17 cases. Factors associated with poor DMFS included tumor necrosis, lymphovascular invasion (LVI), perineural invasion, and histologic compact type. Postoperative carbohydrate antigen 19-9, tumor necrosis, LVI, and close/positive margin were associated with poor OS. LVI emerged as a key factor affecting both DMFS and OS, with a 5-year OS of 93.3% for patients without LVI compared to 35.8% with LVI. Based on these factors, a nomogram predicting 3-year and 5-year DMFS and OS was developed, demonstrating high concordance with actual survival in the cohort (Harrell C-index 0.809 for OS, 0.801 for DMFS, respectively).
Conclusion
The prognosis of cHCC-CCA is notably poor when combined with LVI. Given the significant impact of adverse features, accurate outcome prediction is crucial. Moreover, consideration of adjuvant therapy may be warranted for patients exhibiting poor survival and increased risk of local recurrence or distant metastasis.
  • 1,324 View
  • 75 Download
Close layer
Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study
Seok-Joo Chun, Eunji Kim, Won Il Jang, Mi-Sook Kim, Hyun-Cheol Kang, Byoung Hyuck Kim, Eui Kyu Chie
Cancer Res Treat. 2024;56(4):1197-1206.   Published online April 11, 2024
DOI: https://doi.org/10.4143/crt.2024.258
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to assess the prognostic significance of bulky nodal involvement in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy.
Materials and Methods
We retrospectively analyzed medical records of patients diagnosed with anal squamous cell carcinoma who underwent definitive chemoradiotherapy at three medical centers between 2004 and 2021. Exclusion criteria included distant metastasis at diagnosis, 2D radiotherapy, and salvage treatment for local relapse. Bulky N+ was defined as nodes with a long diameter of 2 cm or greater.
Results
A total of 104 patients were included, comprising 51 with N0, 46 with non-bulky N+, and seven with bulky N+. The median follow-up duration was 54.0 months (range, 6.4 to 162.2 months). Estimated 5-year progression-free survival (PFS), loco-regional recurrence-free survival (LRRFS), and overall survival (OS) rates for patients with bulky N+ were 42.9%, 42.9%, and 47.6%, respectively. Bulky N+ was significantly associated with inferior PFS, LRRFS, and OS compared to patients without or with non-bulky N+, even after multivariate analysis. We proposed a new staging system incorporating bulky N+ as N2 category, with estimated 5-year LRRFS, PFS, and OS rates of 81.1%, 80.6%, and 86.2% for stage I, 67.7%, 60.9%, and 93.3% for stage II, and 42.9%, 42.9%, and 47.6% for stage III disease, enhancing the predictability of prognosis.
Conclusion
Patients with bulky nodal disease treated with standard chemoradiotherapy experienced poor survival outcomes, indicating the potential necessity for further treatment intensification.
  • 1,263 View
  • 70 Download
Close layer
The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis
Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2024;56(3):809-824.   Published online December 14, 2023
DOI: https://doi.org/10.4143/crt.2023.920
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is increasing interest in the efficacy of stereotactic ablative radiotherapy (SABR) for treating colorectal cancer (CRC) patients with oligometastases (OM), recently. The purpose of this meta-analysis was to evaluate local control (LC), progression-free survival (PFS), and overall survival (OS) of CRC patients with pulmonary OM treated with SABR and toxicities.
Materials and Methods
Studies that reported SABR for CRC patients with pulmonary OM were searched from MEDLINE and Embase. Treatment outcomes including LC, PFS, OS, and toxicities of grade 3 or higher were assessed.
Results
A total of 19 studies with 1,668 patients were chosen for this meta-analysis. Pooled 1-, 2-, and 3-year LC rates were 83.1%, 69.3%, and 63.9%, respectively. PFS rates were 44.8%, 26.5%, and 21.5% at 1, 2, and 3 years, respectively. OS rates at 1-, 2-, and 3-year were 87.5%, 69.9%, and 60.5%, respectively. The toxicity rate of grade 3 or higher was 3.6%. The effect of dose escalation was meta-analyzed using available studies.
Conclusion
Application of SABR to CRC patients with pulmonary OM achieved modest local control with acceptable toxicity according to the present meta-analysis. Further studies establishing the clinical efficacy of SABR are guaranteed.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • 3,230 View
  • 153 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
General
Radiation Oncologists’ Perspectives on Oligometastatic Disease: A Korean Survey Study
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn, on behalf of the Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2024;56(2):414-421.   Published online November 22, 2023
DOI: https://doi.org/10.4143/crt.2023.876
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Perspectives of radiation oncologists on oligometastatic disease was investigated using multi-layered survey.
Materials and Methods
Online survey on the oligometastatic disease was distributed to the board-certified regular members of the Korean Society for Radiation Oncology. The questionnaire consisted of four domains: five questions on demographics; five on the definition of oligometastatic disease; four on the role of local therapy; and three on the oligometastatic disease classification, respectively.
Results
A total of 135 radiation oncologists participated in the survey. The median length of practice after board certification was 22.5 years (range, 1 to 44 years), and the vast majority (94.1%) answered affirmatively to the clinical experience in oligometastatic disease management. Nearly two-thirds of the respondents considered the number of involved organs as an independent factor in defining oligometastasis. Most frequently perceived upper limit on the numerical definition of oligometastasis was 5 (64.2%), followed by 3 (26.0%), respectively. Peritoneal and brain metastasis were nominated as the sites to be excluded from oligometastastic disease by 56.3% and 12.6% of the participants, respectively. Vast majority (82.1%) agreed on the role of local treatment in the management of oligometastatic disease. Majority (72%) of the participants acknowledged the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) classification of oligometastatic disease, however, only 43.3% answered that they applied this classification in their clinical practice. Underlying reasons against the clinical use were ‘too complicated’ (66.0%), followed by ‘insufficient supporting evidence’ (30.0%), respectively.
Conclusion
While most radiation oncologists supported the role of local therapy in oligometastatic disease, there were several inconsistencies in defining and categorizing oligometastatic disease. Continued education and training on oligometastatic disease would be also required to build consensus among participating caregivers.

Citations

Citations to this article as recorded by  
  • Efficacy Analysis of Hypofractionated Radiotherapy for Oligometastatic Tumors: A Retrospective Study
    Qian Sun, Hanqing Zhao, Xianwen Zhang, Suli Zhang, Zelai He, Gengming Wang, Hao Jiang, Aili Xuan, Xianming Li
    Technology in Cancer Research & Treatment.2025;[Epub]     CrossRef
  • A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation
    Hanseung Kang, Woohyeon Do, Yong Chan Ahn, Eui Kyu Chie, Chai Hong Rim
    European Journal of Cancer.2024; 212: 115043.     CrossRef
  • 2,870 View
  • 139 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Gastrointestinal cancer
Risk Factors for Distant Metastasis in Extrahepatic Bile Duct Cancer after Curative Resection (KROG 1814)
Younghee Park, Tae Hyun Kim, Kyubo Kim, Jeong Il Yu, Wonguen Jung, Jinsil Seong, Woo Chul Kim, Jin Hwa Choi, Ah Ram Chang, Bae Kwon Jeong, Byoung Hyuck Kim, Tae Gyu Kim, Jin Hee Kim, Hae Jin Park, Hyun Soo Shin, Jung Ho Im, Eui Kyu Chie
Cancer Res Treat. 2024;56(1):272-279.   Published online July 31, 2023
DOI: https://doi.org/10.4143/crt.2023.616
AbstractAbstract PDFPubReaderePub
Purpose
Risk factors predicting distant metastasis (DM) in extrahepatic bile duct cancer (EHBDC) patients treated with curative resection were investigated.
Materials and Methods
Medical records of 1,418 EHBDC patients undergoing curative resection between Jan 2000 and Dec 2015 from 14 institutions were reviewed. After resection, 924 patients (67.6%) were surveilled without adjuvant therapy, 297 (21.7%) were treated with concurrent chemoradiotherapy (CCRT) and 148 (10.8%) with CCRT followed by chemotherapy. To exclude the treatment effect from innate confounders, patients not treated with adjuvant therapy were evaluated.
Results
After a median follow-up of 36.7 months (range, 2.7 to 213.2 months), the 5-year distant metastasis-free survival (DMFS) rate was 57.7%. On multivariate analysis, perihilar or diffuse tumor (hazard ratio [HR], 1.391; p=0.004), poorly differentiated histology (HR, 2.014; p < 0.001), presence of perineural invasion (HR, 1.768; p < 0.001), positive nodal metastasis (HR, 2.670; p < 0.001) and preoperative carbohydrate antigen (CA) 19-9 ≥ 37 U/mL (HR, 1.353; p < 0.001) were significantly associated with inferior DMFS. The DMFS rates significantly differed according to the number of these risk factors. For validation, patients who underwent adjuvant therapy were evaluated. In patients with ≥ 3 factors, additional chemotherapy after CCRT resulted in a superior DMFS compared with CCRT alone (5-year rate, 47.6% vs. 27.7%; p=0.001), but the benefit of additional chemotherapy was not observed in patients with 0-2 risk factors.
Conclusion
Tumor location, histologic differentiation, perineural invasion, lymph node metastasis, and preoperative CA 19-9 level predicted DM risk in resected EHBDC. These risk factors might help identifying a subset of patients who could benefit from additional chemotherapy after resection.
  • 3,107 View
  • 188 Download
Close layer
Editorial
Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
Cancer Res Treat. 2023;55(4):1063-1064.   Published online June 27, 2023
DOI: https://doi.org/10.4143/crt.2023.780
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Oligometastasis: Expansion of Curative Treatments in the Field of Oncology
    Ah Reum Lim, Chai Hong Rim
    Medicina.2023; 59(11): 1934.     CrossRef
  • 2,506 View
  • 203 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Original Article
Gastrointestinal cancer
Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group’s Comparative Survey Study
Won Kyung Cho, Gyu Sang Yoo, Chai Hong Rim, Jae-Uk Jeong, Eui Kyu Chie, Yong Chan Ahn, Hyeon-Min Cho, Jun Won Um, Yang-Gun Suh, Ah Ram Chang, Jong Hoon Lee, On behalf of the Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2023;55(4):1281-1290.   Published online June 7, 2023
DOI: https://doi.org/10.4143/crt.2023.479
AbstractAbstract PDFPubReaderePub
Purpose
Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary.
Materials and Methods
A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties.
Results
The radiation oncologists chose “bone” more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored “peritoneal seeding” (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that “irrelevant, if all metastatic lesions are amendable to local therapy”, while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed.
Conclusion
This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.

Citations

Citations to this article as recorded by  
  • Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
    Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(4): 1063.     CrossRef
  • 2,838 View
  • 176 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Review Article
Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Cancer Association Oligometastasis Working Group
Cancer Res Treat. 2023;55(3):707-719.   Published online March 15, 2023
DOI: https://doi.org/10.4143/crt.2022.1599
AbstractAbstract PDFPubReaderePub
Introduction of the concept for oligometastasis led to wide application of metastasis-directed local ablative therapies for metastatic colorectal cancer (CRC). By application of the metastasis-directed local ablative therapies including surgical resection, radiofrequency ablation (RFA), and stereotactic ablative body radiotherapy (SABR), the survival outcomes of patients with metastatic CRC have improved. The liver is the most common distant metastatic site in CRC patients, and recently various metastasis-directed local therapies for hepatic oligometastasis from CRC (HOCRC) are widely used. Surgical resection is the first line of metastatic-directed local therapy for HOCRC, but its eligibility is very limited. Alternatively, RFA can be applied to patients who are ineligible for surgical resection of liver metastasis. However, there are some limitations such as inferior local control (LC) compared with surgical resection and technical feasibility based on location, size, and visibility on ultrasonography of the liver metastasis. Recent advances in radiation therapy technology have led to an increase in the use of SABR for liver tumors. SABR is considered complementary to RFA for patients with HOCRC who are ineligible for RFA. Furthermore, SABR can potentially result in better LC for liver metastases > 2-3 cm compared with RFA. In this article, the previous studies regarding curative metastasis-directed local therapies for HOCRC based on the radiation oncologist’s and surgeon’s perspective are reviewed and discussed. In addition, future perspectives regarding SABR in the treatment of HOCRC are suggested.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
    Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
    Radiation Oncology Journal.2024; 42(4): 247.     CrossRef
  • 5,143 View
  • 287 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Original Articles
Gastrointestinal cancer
One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials
Soo-Yoon Sung, Dae Yong Kim, Hong Seok Jang, Tae Hyun Kim, Hee Chul Park, Eui Kyu Chie, Taek-Keun Nam, Sung Hwan Kim, Jong Hoon Lee
Cancer Res Treat. 2023;55(3):918-926.   Published online February 27, 2023
DOI: https://doi.org/10.4143/crt.2022.1646
AbstractAbstract PDFPubReaderePub
Purpose
The optimal short-course chemotherapeutic regimen for rectal cancer has not been clearly defined until now. KROG 10-01 and KROG 11-02 prospective trials investigated the efficacy and safety of 1- and 2-week chemoradiotherapy (CRT), respectively.
Materials and Methods
Patients eligible for KROG 10-01 and KROG 11-02 involved those with clinical T3-4N0-2M0 rectal cancers. They received preoperative CRT and total mesorectal excision. Patients in KROG 10-01 received radiation of 25 Gy in 5 fractions during 1 week with 5-fluorouracil/leucovorin. Patients in KROG 11-02 received radiation of 33 Gy in 10 fractions for 2 weeks with oral capecitabine.
Results
A total of 150 patients consisting of 70 patients from KROG 10-01 and 80 patients from KROG 11-02 were collectively analyzed. With a median follow-up time of 89.2 months, the 5-year overall survival rate was 86.5% in 1-week CRT and 85.3% in 2-week CRT (p=0.841). The 5-year recurrence-free survival rate was 83.5% in 1-week CRT and 77.1% in 2-week CRT (p=0.448). One patient (1.4%) in 1-week CRT and 11 patients (13.8%) in 2-week CRT exhibited pathologic complete regression (ypT0N0M0) after radiotherapy (p=0.006). One-week CRT had significantly higher acute hematologic (12.8% vs. 3.8%, p=0.040) and nonhematologic (38.6% vs. 16.3%, p=0.002) toxicity than 2-week CRT.
Conclusion
Both 1- and 2-week schedules of CRT showed favorable survival outcomes after 7 years of follow-up. But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course.
  • 2,945 View
  • 152 Download
  • 1 Web of Science
Close layer
General
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Eui Kyu Chie, Yong Chan Ahn, The Oligometastasis Working Group, Korea Cancer Association
Cancer Res Treat. 2022;54(4):953-969.   Published online August 16, 2022
DOI: https://doi.org/10.4143/crt.2022.329
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method.
Materials and Methods
Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS).
Results
A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm.
Conclusion
Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT’s demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer
    Mara B. Antonoff, Kyle G. Mitchell, Samuel S. Kim, Hai V. Salfity, Svetlana Kotova, Robert Taylor Ripley, Alfonso L. Neri, Pallavi Sood, Saumil G. Gandhi, Yasir Y. Elamin, Jessica S. Donington, David R. Jones, Elizabeth A. David, Stephen G. Swisher, Isabe
    The Annals of Thoracic Surgery.2025;[Epub]     CrossRef
  • Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma
    Boyu Leng, Haohua Wang, Yunfan Ge, Xiaoli Sun, Pingping Dong, Xinzhe Dong, Xuezhang Duan, Quan Wang, Yaoxiong Xia, Lijuan Ding, Honghai Dai, Tianxing Liu, Fang Shi, Xiang Zhang, Jinbo Yue
    International Journal of Radiation Oncology*Biology*Physics.2025;[Epub]     CrossRef
  • Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma
    Gowoon Yang, Kyung Hwan Kim, Chang Geol Lee, Min Hee Hong, Hye Ryun Kim, Yeona Cho, Hong In Yoon
    Cancer Research and Treatment.2024; 56(1): 115.     CrossRef
  • MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters
    Mette van Overeem Felter, Pia Krause Møller, Mirjana Josipovic, Susanne Nørring Bekke, Uffe Bernchou, Eva Serup-Hansen, Kasper Madsen, Parag J. Parikh, Joshua Kim, Poul Geertsen, Claus P. Behrens, Ivan R. Vogelius, Mette Pøhl, Tine Schytte, Gitte Fredberg
    Radiotherapy and Oncology.2024; 192: 110090.     CrossRef
  • Clinical implication of neck dissection for metastatic lymph nodes originating from non-head and neck regions
    Min Ji Kim, So Hee Kang, MinSu Kwon, Young Ho Jung, Seung-Ho Choi, Soon Yuhl Nam, Yoon Se Lee
    Acta Oto-Laryngologica.2024; 144(2): 153.     CrossRef
  • Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability
    Shruti Koti, Lyudmyla Demyan, Gary Deutsch, Matthew Weiss
    Annals of Surgical Oncology.2024; 31(6): 4031.     CrossRef
  • Radiation Oncologists’ Perspectives on Oligometastatic Disease: A Korean Survey Study
    Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn
    Cancer Research and Treatment.2024; 56(2): 414.     CrossRef
  • Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
    Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
    Current Oncology.2024; 31(6): 3239.     CrossRef
  • Local Ablative Therapy Combined With Pembrolizumab in Patients With Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis
    Hye In Lee, Eun Kyung Choi, Su Ssan Kim, Young Seob Shin, Junhee Park, Chang-Min Choi, Shinkyo Yoon, Hyeong Ryul Kim, Young Hyun Cho, Si Yeol Song
    International Journal of Radiation Oncology*Biology*Physics.2024; 120(3): 698.     CrossRef
  • Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors
    Jamie Lütscher, Hans Gelpke, Adrian Zehnder, Laetitia Mauti, Christian Padevit, Hubert John, Nidar Batifi, Daniel Rudolf Zwahlen, Robert Förster, Christina Schröder
    Cancers.2024; 16(15): 2655.     CrossRef
  • A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation
    Hanseung Kang, Woohyeon Do, Yong Chan Ahn, Eui Kyu Chie, Chai Hong Rim
    European Journal of Cancer.2024; 212: 115043.     CrossRef
  • Oligometastasis: More Lessons to Be Learned
    Kyung Hwan Kim, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(1): 1.     CrossRef
  • Top Ten Lessons Learned from Trials in Oligometastatic Cancers
    Vivian S. Tan, David A. Palma
    Cancer Research and Treatment.2023; 55(1): 5.     CrossRef
  • Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
    Rongxin Liao, Kehong Chen, Jinjin Li, Hengqiu He, Guangming Yi, Mingfeng Huang, Rongrong Chen, Lu Shen, Xiaoyue Zhang, Zaicheng Xu, Zhenzhou Yang, Yuan Peng
    Cancer Research and Treatment.2023; 55(3): 814.     CrossRef
  • Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
    Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
    Cancer Research and Treatment.2023; 55(3): 707.     CrossRef
  • Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
    Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(4): 1063.     CrossRef
  • Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
    Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
    Radiation Oncology.2023;[Epub]     CrossRef
  • Oligometastasis: Expansion of Curative Treatments in the Field of Oncology
    Ah Reum Lim, Chai Hong Rim
    Medicina.2023; 59(11): 1934.     CrossRef
  • Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment
    Dae Ho Lee
    Cancer Research and Treatment.2022; 54(4): 951.     CrossRef
  • 6,810 View
  • 334 Download
  • 20 Web of Science
  • 20 Crossref
Close layer
Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis
Bum-Sup Jang, Ji-Hyun Chang, Seung Hyuck Jeon, Myung Geun Song, Kyung-Hun Lee, Seock-Ah Im, Jong-Il Kim, Tae-You Kim, Eui Kyu Chie
Cancer Res Treat. 2022;54(2):383-395.   Published online August 24, 2021
DOI: https://doi.org/10.4143/crt.2021.759
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The value of the genomic profiling by targeted gene-sequencing on radiation therapy response prediction was evaluated through integrated analysis including clinical information. Radiation response prediction model was constructed based on the analyzed findings.
Materials and Methods
Patients who had the tumor sequenced using institutional cancer panel after informed consent and received radiotherapy for the measurable disease served as the target cohort. Patients with irradiated tumor locally controlled for more than 6 months after radiotherapy were defined as the durable local control (DLC) group, otherwise, non-durable local control (NDLC) group. Significant genomic factors and domain knowledge were used to develop the Bayesian Network model to predict radiotherapy response.
Results
Altogether, 88 patients were collected for analysis. Of those, 41 (43.6%) and 47 (54.4%) patients were classified as the NDLC and DLC group, respectively. Somatic mutations of NOTCH2 and BCL were enriched in the NDLC group, whereas, mutations of CHEK2, MSH2, and NOTCH1 were more frequently found in the DLC group. Altered DNA repair pathway was associated with better local failure–free survival (hazard ratio, 0.40; 95% confidence interval, 0.19 to 0.86; p=0.014). Smoking somatic signature was found more frequently in the DLC group. Area under the receiver operating characteristic curve of the Bayesian network model predicting probability of 6-month local control was 0.83.
Conclusion
Durable radiation response was associated with alterations of DNA repair pathway and smoking somatic signature. Bayesian network model could provide helpful insights for high precision radiotherapy. However, these findings should be verified in prospective cohort for further individualization.

Citations

Citations to this article as recorded by  
  • Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22–13)
    Bum-Sup Jang, Seok-Joo Chun, Hyeon Seok Choi, Ji Hyun Chang, Kyung Hwan Shin
    Computer Methods and Programs in Biomedicine.2024; 245: 108049.     CrossRef
  • Prediction of Overall Disease Burden in (y)pN1 Breast Cancer Using Knowledge-Based Machine Learning Model
    Seok-Joo Chun, Bum-Sup Jang, Hyeon Seok Choi, Ji Hyun Chang, Kyung Hwan Shin
    Cancers.2024; 16(8): 1494.     CrossRef
  • Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
    I-Shiow Jan, Hui Ju Ch’ang
    Radiation Oncology.2023;[Epub]     CrossRef
  • Characterization of the gene signature correlated with favorable response to chemoradiotherapy in rectal cancer: A hypothesis‐generating study
    Seung Hyuck Jeon, Eui Kyu Chie
    Cancer Medicine.2023; 12(7): 8981.     CrossRef
  • Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma
    Yi-Chih Tsai, Min-Chieh Hsin, Rui-Jun Liu, Ting-Wei Li, Hui-Ju Ch’ang
    Cancers.2023; 15(21): 5212.     CrossRef
  • 5,752 View
  • 183 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Editorial
The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer?
Eui Kyu Chie, Yong Chan Ahn
Cancer Res Treat. 2021;53(3):609-610.   Published online June 16, 2021
DOI: https://doi.org/10.4143/crt.2021.707
PDFPubReaderePub
  • 5,158 View
  • 184 Download
Close layer
Original Article
Gastrointestinal Cancer
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Kyung-Hun Lee, Eui Kyu Chie, Seock-Ah Im, Jee Hyun Kim, Jihyun Kwon, Sae-Won Han, Do-Youn Oh, Jin-Young Jang, Jae-Sung Kim, Tae-You Kim, Yung-Jue Bang, Sun Whe Kim, Sung W. Ha
Cancer Res Treat. 2021;53(4):1096-1103.   Published online December 30, 2020
DOI: https://doi.org/10.4143/crt.2020.928
AbstractAbstract PDFPubReaderePub
Purpose
Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed.
Materials and Methods
Patients with curatively resected stage IB-IIB pancreatic adenocarcinoma were eligible. Treatment consisted of chemotherapy with gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 every 3 weeks for two cycles, followed by chemoradiotherapy (50.4 Gy/28 fx) with weekly gemcitabine (300 mg/m2/wk), and then gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks for four cycles. The primary endpoint was 1-year disease-free survival rate. The secondary endpoints were disease-free survival, overall survival, and safety.
Results
Seventy-four patients were enrolled. One-year disease-free survival rate was 57.9%. Median disease-free and overall survival were 15.0 months (95% confidence interval [CI], 11.6 to 18.4) and 33.0 months (95% CI, 21.8 to 44.2), respectively. At the median follow-up of 32 months, 57 patients (77.0%) had recurrence including 11 patients whose recurrence was during the adjuvant treatment. Most of the recurrences were systemic (52 patients). Stage at the time of diagnosis (70.0% in IIA, 51.2% in IIB, p=0.006) were significantly related with 1-year disease-free survival rate. Toxicities were generally tolerable, with 53 events of grade 3 or 4 hematologic toxicity and four patients with febrile neutropenia.
Conclusion
Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine and maintenance gemcitabine showed efficacy and good tolerability in curatively resected pancreatic cancer.

Citations

Citations to this article as recorded by  
  • NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis
    Xiao-Dong Huang, Yong-Wei Chen, Lv Tian, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Dong-Dong Lin, Feng-Jun Xiao
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis
    Obaid Ur Rehman, Eeshal Fatima, Zain Ali Nadeem, Arish Azeem, Jatin Motwani, Habiba Imran, Hadia Mehboob, Alishba Khan, Omer Usman
    Journal of Gastrointestinal Cancer.2024; 55(2): 559.     CrossRef
  • OTUB1/NDUFS2 axis promotes pancreatic tumorigenesis through protecting against mitochondrial cell death
    Xiao-Dong Huang, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Qiao-Wei Liu, Yi-Wu Wang, Ya-Jin Liao, Dong-Dong Lin, Feng-Jun Xiao
    Cell Death Discovery.2024;[Epub]     CrossRef
  • Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center
    Johannes Felix Englisch, Alexander Englisch, Dominik Dannehl, Kenneth Eissler, Christian Martin Tegeler, Sabine Matovina, Léa Louise Volmer, Diethelm Wallwiener, Sara Y. Brucker, Andreas Hartkopf, Tobias Engler
    Archives of Gynecology and Obstetrics.2024;[Epub]     CrossRef
  • A Photothermal Therapy Study Based on Electrospinning Nanofibers Blended and Coated with Polydopamine Nanoparticles
    Chunhong Sui, Yijia Luo, Xiao Xiao, Jiaxue Liu, Xiaotong Shao, Yingxue Xue, Cheng Wang, Wenliang Li
    ChemistrySelect.2023;[Epub]     CrossRef
  • Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
    Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • CircLMTK2 Silencing Attenuates Gemcitabine Resistance in Pancreatic Cancer by Sponging miR-485-5p and to Target PAK1
    Yeting Lu, Shuping Zhou, Gong Cheng, Yi Ruan, Yuan Tian, Kaiji Lv, Shuo Han, Xinhua Zhou, Xiangya Ding
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Effects of Radiotherapy and Chemotherapy on Postoperative Prognosis of Patients Undergoing Radical Surgery for Pancreatic Cancer—Based on SEER Database Analysis
    媛媛 苏
    Advances in Clinical Medicine.2022; 12(10): 9540.     CrossRef
  • Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
    Alice Usai, Gregorio Di Franco, Margherita Piccardi, Perla Cateni, Luca Emanuele Pollina, Caterina Vivaldi, Enrico Vasile, Niccola Funel, Matteo Palmeri, Luciana Dente, Alfredo Falcone, Dimitri Giunchi, Alessandro Massolo, Vittoria Raffa, Luca Morelli
    Cancers.2021; 13(16): 4131.     CrossRef
  • Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21
    Peng Chen, Zhiwei He, Jie Wang, Jian Xu, Xueyi Jiang, Yankun Chen, Xinyuan Liu, Jianxin Jiang
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • 6,739 View
  • 152 Download
  • 10 Crossref
Close layer
Special Article
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(3):851-860.   Published online June 7, 2019
DOI: https://doi.org/10.4143/crt.2019.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by  
  • Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia
    Ljerka Armano, Vanja Vasiljev, Tomislav Rukavina, Denis Juraga, Aleksandar Racz, Vanja Tešić
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
    H Çelik, H Aslan
    Nigerian Journal of Clinical Practice.2024; 27(4): 415.     CrossRef
  • Complementary and alternative medicine use and its impact on quality of life among cancer patients in Freetown, Sierra Leone: considerations for a resource-limited setting
    Onome T. Abiri, Matilda Seinya Sheriff, Isaac O. Smalle, Nellie V.T. Bell, Ibrahim Franklyn Kamara, Thaim B. Kamara, Constance Cummings-John, Joshua Coker, Abdulai Jawo Bah, Joseph Sam Kanu, Ronita Luke, Lannes Kamara, John Smith, Mohamed Samai
    Discover Medicine.2024;[Epub]     CrossRef
  • Cancer care beyond the conventional: Challenges of integrative oncology in India
    Parvathy Venate, Vitthal G. Huddar
    Ayush Journal of Integrative Oncology.2024; 1(3 & 4): 35.     CrossRef
  • Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
    Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
    Complementary Therapies in Medicine.2023; 72: 102920.     CrossRef
  • Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
    Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
    Cancer Research and Treatment.2023; 55(2): 442.     CrossRef
  • Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
    Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
    Journal of Integrative Medicine.2023; 21(4): 377.     CrossRef
  • Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
    Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
    Journal of Community Health.2022; 47(2): 284.     CrossRef
  • Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
    Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
    Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
    Jeongwon Yeom, Jung Mi Lee
    Clinical Nutrition Research.2022; 11(4): 255.     CrossRef
  • Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
    Kyeore Bae
    The Journal of Internal Korean Medicine.2022; 43(6): 1075.     CrossRef
  • Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
    Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
    Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122.     CrossRef
  • Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
    Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
    Cukurova Medical Journal.2021; 46(2): 574.     CrossRef
  • The Current Status of Integrative Oncology in Korea
    Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
    Integrative Cancer Therapies.2021;[Epub]     CrossRef
  • Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
    Kathryn Knecht, David Kinder, Amy Stockert
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
    Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • 9,378 View
  • 225 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Original Articles
The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression
Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim
Cancer Res Treat. 2019;51(4):1324-1335.   Published online January 29, 2019
DOI: https://doi.org/10.4143/crt.2018.653
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the effectiveness and safety of spinal stereotactic radiosurgery (SRS) in treating spinal metastasis with epidural spinal cord compression (ESCC).
Materials and Methods
During 2013-2016, 149 regions of spinal metastasis in 105 patients treated with singlefraction (12-24 Gy) spinal SRS were reviewed. Cord compression of Bilsky grade 2 (with visible cerebrospinal fluid [CSF]) or 3 (no visible CSF) was defined as ESCC. Local progression (LP) and vertebral compression fracture (VCF) rates after SRS were evaluated using multivariate competing-risk regression analysis.
Results
The 1-year cumulative incidences of LP for Bilsky grades 0 (n=80), 1 (n=39), 2 (n=21), and 3 (n=9) were 3.0%, 8.4%, 0%, and 24.9%, respectively. Bilsky grade 2 ESCC did not significantly increase the LP rate (no LP for grade 2). The 1-year cumulative incidences of VCF for Bilsky grades 0, 1, 2, and 3 were 6.6%, 5.2%, 17.1%, and 12.1%, respectively. ESCC may increase VCF risk (subhazard ratio [SHR] for grade 2, 5.368; p=0.035; SHR for grade 3, 2.215; p=0.460). Complete or partial pain response rates after SRS were 79%, 78%, 53%, and 63% for Bilsky grades 0, 1, 2, and 3, respectively (p=0.008). No neurotoxicity of grade ≥ 3 was observed.
Conclusion
Spinal SRS for spinal metastasis with Bilsky grade 2 ESCC did not increase the LP rate, was not associated with severe neurotoxicity, and showed moderate VCF and pain response rates. Bilsky grade 3 had a high LP rate.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
    R.S. Guninski, F. Cuccia, F. Alongi, N. Andratschke, C. Belka, D. Bellut, M. Dahele, M. Josipovic, T.E. Kroese, P. Mancosu, G. Minniti, M. Niyazi, U Ricardi, P. Munck af Rosenschold, A. Sahgal, Y. Tsang, W.F.A.R. Verbakel, M. Guckenberger
    Radiotherapy and Oncology.2024; 190: 109969.     CrossRef
  • Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy?
    O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya
    Creative surgery and oncology.2024; 14(2): 127.     CrossRef
  • Surgical Interventions Following Radiotherapy in Spinal Metastases with Intermediate Instability: A Risk Factor Analysis: The Korean Society of Spinal Tumor Multicenter Study (KSST 2022-02)
    Se-Jun Park, Jin Ho Kim, Yong Chan Ahn, Woong Sub Koom, Hwa Kyung Byun, Young-Hoon Kim, Sang-Il Kim, Dong-Ho Kang
    Cancers.2024; 16(14): 2554.     CrossRef
  • Development of a novel 12-point grading system for evaluating epidural spinal cord compression and its clinical implications
    Xuyong Cao, Weihao Jiang, Xiongwei Zhao, Haikuan Yu, Mingxing Lei, Yuncen Cao, Xiuyun Su, Yaosheng Liu
    The Spine Journal.2023; 23(12): 1858.     CrossRef
  • Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
    Dong-Ho Kang, Wooseok Lee, Bong-Soon Chang, Hyoungmin Kim, Sam Yeol Chang, Seong Hwa Hong, Jin Ho Kim, Hee Jung Son
    Cancers.2023; 15(23): 5518.     CrossRef
  • Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases
    Chengcheng Gui, Xuguang Chen, Khadija Sheikh, Liza Mathews, Sheng-Fu L. Lo, Junghoon Lee, Majid A. Khan, Daniel M. Sciubba, Kristin J. Redmond
    Journal of Neurosurgery: Spine.2022; 36(2): 294.     CrossRef
  • Stereotactic body radiotherapy for spinal metastases: a review
    Lanlan Guo, Lixin Ke, Ziyi Zeng, Chuanping Yuan, Ziwei Wu, Lei Chen, Lixia Lu
    Medical Oncology.2022;[Epub]     CrossRef
  • Treatment of Metastatic Spinal Disease; what the Radiologist needs to know
    Stephen Supple, Shahjehan Ahmad, Santhosh Gaddikeri, Miral D. Jhaveri
    The British Journal of Radiology.2022;[Epub]     CrossRef
  • Spinal metastases 2021: a review of the current state of the art and future directions
    Daniel M. Sciubba, Zach Pennington, Matthew W. Colman, C. Rory Goodwin, Ilya Laufer, Joshua C. Patt, Kristin J. Redmond, Philip Saylor, John H. Shin, Joseph H. Schwab, Andrew J. Schoenfeld
    The Spine Journal.2021; 21(9): 1414.     CrossRef
  • An updated algorithm for the treatment of spinal metastasis
    Kawngwoo Park, Seong Son, Sang Gu Lee, En Kyung Cho, Hee Kyung Ahn, In Keun Park, Sun Jin Sym, Young Saing Kim
    Journal of the Korean Society of Stereotactic and Functional Neurosurgery.2021; 17(2): 70.     CrossRef
  • Separation surgery for metastatic epidural spinal cord compression: A qualitative review
    Giuseppe Di Perna, Fabio Cofano, Cristina Mantovani, Serena Badellino, Nicola Marengo, Marco Ajello, Ludovico Maria Comite, Giuseppe Palmieri, Fulvio Tartara, Francesco Zenga, Umberto Ricardi, Diego Garbossa
    Journal of Bone Oncology.2020; 25: 100320.     CrossRef
  • Multidisciplinary management of metastatic spine disease: initial symptom-directed management
    Jeremy M Steinberger, Frank Yuk, Amish H Doshi, Sheryl Green, Isabelle M Germano
    Neuro-Oncology Practice.2020; 7(Supplement): i33.     CrossRef
  • 9,882 View
  • 232 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Impact of Mucin Proportion in the Pretreatment MRI on the Outcomes of Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
Eunji Kim, Kyubo Kim, Se Hyung Kim, Sae-Won Han, Tae-You Kim, Seung-Yong Jeong, Kyu Joo Park, Jaemoon Koh, Gyeong Hoon Kang, Eui Kyu Chie
Cancer Res Treat. 2019;51(3):1188-1197.   Published online December 20, 2018
DOI: https://doi.org/10.4143/crt.2018.434
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate treatment response to neoadjuvant chemoradiotherapy (CRT) with regard to mucin status in pathology and pretreatment magnetic resonance imaging (MRI) in locally advanced rectal cancer.
Materials and Methods
Between 2003 and 2011, 306 patients with locally advanced rectal cancer received neoadjuvant CRT followed by surgery, and mucinous adenocarcinoma (MAC) was found in 27 (8.8%). All MAC patients had MRI before and after CRT and mucin proportion at MRI was measured. Therapeutic response was assessed by pathology after total mesorectal excision. To determine the optimal cut-off for mucin proportion in predicting good CRT response (near total or total regression) and negative circumferential resection margin (CRM), the receiver-operating characteristic analysis was performed.
Results
After neoadjuvant CRT, overall downstaging occurred in 44.4% of MAC and 72.4% of non-MAC (p=0.001), and positive CRM (≤1 mm) was observed more frequently in MAC (p<0.001). The optimal threshold for treatment response was 30% for mucin proportion, and there are nine with low mucin proportion (<30%) and 18 with high mucin proportion (≥30%) in pretreatment MRI. Negative CRM and tumor downstaging occurred more common in patients with mucin <30%, although statistically insignificant (p=0.071 and p=0.072, respectively). Regarding oncologic outcomes, lower mucin proportion in pretreatment MRI was associated with better disease-free and overall survival in MAC group (p=0.092 and 0.056, respectively), but the difference did not reach statistical significance.
Conclusion
Poor treatment outcome with neoadjuvant CRT was observed in patients with MAC, especially those with high mucin proportion at pretreatment MRI.

Citations

Citations to this article as recorded by  
  • Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma
    Xiangwen Tan, Yiwei Zhang, Xiaofeng Wu, Qing Fang, Yunhua Xu, Shuxiang Li, Jinyi Yuan, Xiuda Peng, Kai Fu, Shuai Xiao
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity‐Matched Analysis
    Leah E. Hendrick, Samer Naffouje, Iman Imanirad, Allan Lima Pereira, Tiago Biachi, Julian Sanchez, Sophie Dessureault, Amalia Stefanou, Sean P. Dineen, Seth Felder
    Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Accelerated T2W Imaging with Deep Learning Reconstruction in Staging Rectal Cancer: A Preliminary Study
    Lan Zhu, Bowen Shi, Bei Ding, Yihan Xia, Kangning Wang, Weiming Feng, Jiankun Dai, Tianyong Xu, Baisong Wang, Fei Yuan, Hailin Shen, Haipeng Dong, Huan Zhang
    Journal of Imaging Informatics in Medicine.2024;[Epub]     CrossRef
  • Mucinous rectal cancers: clinical features and prognosis in a population-based cohort
    Malin Enblad, Klara Hammarström, Joakim Folkesson, Israa Imam, Milan Golubovik, Bengt Glimelius
    BJS Open.2022;[Epub]     CrossRef
  • Mucin-Containing Rectal Cancer: A Review of Unique Imaging, Pathology, and Therapeutic Response Features
    David D. Childs, Caio Max Sao Pedro Rocha Lima, Yi Zhou
    Seminars in Roentgenology.2021; 56(2): 186.     CrossRef
  • Advances in radiological staging of colorectal cancer
    R.J. Goiffon, A. O'Shea, M.G. Harisinghani
    Clinical Radiology.2021; 76(12): 879.     CrossRef
  • A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer
    Klara Hammarström, Israa Imam, Artur Mezheyeuski, Joakim Ekström, Tobias Sjöblom, Bengt Glimelius
    Cancers.2020; 13(1): 16.     CrossRef
  • 8,335 View
  • 172 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
Cancer Res Treat. 2019;51(2):696-705.   Published online August 13, 2018
DOI: https://doi.org/10.4143/crt.2018.249
AbstractAbstract PDFPubReaderePub
Purpose
Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
Materials and Methods
Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distributionwere assayed bywestern blot for cleaved caspase-3, γH2AX staining, and flow cytometry, respectively.
Results
DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells.
Conclusion
Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.

Citations

Citations to this article as recorded by  
  • The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
    Xi‐Xi Li, Jia‐Kun Xu, Wei‐Jie Su, Hong‐Lin Wu, Kun Zhao, Chang‐Ming Zhang, Xiang‐Kun Chen, Li‐Xuan Yang
    The Kaohsiung Journal of Medical Sciences.2024; 40(2): 161.     CrossRef
  • Glioblastoma Therapy: Past, Present and Future
    Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch, Begoña Pineda, Julia Gutiérrez-Arroyo, Alba Loras, Luis Gonzalez-Bonet, Conrado Martinez-Cadenas, José Estrela, María Marqués-Torrejón
    International Journal of Molecular Sciences.2024; 25(5): 2529.     CrossRef
  • Exploring Disulfiram’s Anticancer Potential: PLGA Nano-Carriers for Prolonged Drug Delivery and Potential Improved Therapeutic Efficacy
    Ibrahim Dumbuya, Ana Maria Pereira, Ibrahim Tolaymat, Adnan Al Dalaty, Basel Arafat, Matt Webster, Barbara Pierscionek, Mouhamad Khoder, Mohammad Najlah
    Nanomaterials.2024; 14(13): 1133.     CrossRef
  • Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma
    Rafael Jiménez, Andrada Constantinescu, Muhube Yazir, Paula Alfonso-Triguero, Raquel Pequerul, Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo
    International Journal of Molecular Sciences.2024; 25(21): 11512.     CrossRef
  • Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review
    Beáta-Mária Benkő, Dimitrios A. Lamprou, Anna Sebestyén, Romána Zelkó, István Sebe
    Expert Opinion on Drug Delivery.2023; 20(4): 541.     CrossRef
  • Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
    Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Löfgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandéus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Øyvind
    JAMA Network Open.2023; 6(3): e234149.     CrossRef
  • Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways
    Yao Liu, Xin Guan, Meiling Wang, Naixue Wang, Yutong Chen, Baolei Li, Zhuxuan Xu, Fangwei Fu, Cheng Du, Zhendong Zheng
    Bioengineered.2022; 13(3): 6579.     CrossRef
  • Disulfiram in glioma: Literature review of drug repurposing
    Shiyu Zhong, Shengyu Liu, Xin Shi, Xudong Zhang, Kunhang Li, Guojun Liu, Lishuai Li, Shanwei Tao, Bowen Zheng, Weichen Sheng, Ziyin Ye, Qichen Xing, Qingqing Zhai, Lijie Ren, Ying Wu, Yijun Bao
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Multimodal targeting of glioma with functionalized nanoparticles
    Hany E. Marei
    Cancer Cell International.2022;[Epub]     CrossRef
  • Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts
    Renyan Tang, Jianmin Zhu, Ying Liu, Ning Wu, Jinbin Han
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells
    Hyeon Ji Kim, Tae-Jun Kim, Yu Gyung Kim, Chaeeun Seong, Jin-Hwa Cho, Wanil Kim, Kyung-Ha Lee, Do-Yeon Kim
    Pharmaceutics.2021; 13(9): 1410.     CrossRef
  • Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
    Chan-Chuan Liu, Cheng-Lin Wu, Meng-Xuan Lin, Chun-I Sze, Po-Wu Gean
    International Journal of Molecular Sciences.2021; 22(19): 10496.     CrossRef
  • Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
    Lisa Zirjacks, Nicolai Stransky, Lukas Klumpp, Lukas Prause, Franziska Eckert, Daniel Zips, Sabine Schleicher, Rupert Handgretinger, Stephan M. Huber, Katrin Ganser
    Biomolecules.2021; 11(11): 1561.     CrossRef
  • The combination of disulfiram and copper for cancer treatment
    Hong Li, Jingyu Wang, Chunfu Wu, Lihui Wang, Zhe-Sheng Chen, Wei Cui
    Drug Discovery Today.2020; 25(6): 1099.     CrossRef
  • Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
    Jinyeong Choi, Gaeun Kim, Su Bin Cho, Hyung-Jun Im
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
    Francisco Meraz-Torres, Sarah Plöger, Claus Garbe, Heike Niessner, Tobias Sinnberg
    Cancers.2020; 12(12): 3538.     CrossRef
  • Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
    Elmira Ekinci, Sagar Rohondia, Raheel Khan, Qingping P. Dou
    Recent Patents on Anti-Cancer Drug Discovery.2019; 14(2): 113.     CrossRef
  • 9,433 View
  • 297 Download
  • 20 Web of Science
  • 17 Crossref
Close layer
The Impact of Surgical Timing on Pathologic Tumor Response after Short Course and Long Course Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma
Sea-Won Lee, Jong Hoon Lee, In Kyu Lee, Seong Taek Oh, Dae Yong Kim, Tae Hyun Kim, Jae Hwan Oh, Ji Yeon Baek, Hee Jin Chang, Hee Chul Park, Hee Cheol Kim, Eui Kyu Chie, Taek-Keun Nam, Hong Seok Jang
Cancer Res Treat. 2018;50(3):1039-1050.   Published online November 21, 2017
DOI: https://doi.org/10.4143/crt.2017.252
AbstractAbstract PDFPubReaderePub
Purpose
A pooled analysis of multi-institutional trials was performed to analyze the effect of surgical timing on tumor response by comparing short course concurrent chemoradiotherapy (CCRT) with long course CCRT followed by delayed surgery in locally advanced rectal cancer.
Materials and Methods
Three hundred patients with cT3-4N0-2 rectal adenocarcinoma were included. Long course patients from KROG 14-12 (n=150) were matched 1:1 to 150 short course patients from KROG 10-01 (NCT01129700) and KROG 11-02 (NCT01431599) according to stage, age, and other risk factors. The primary endpoint was to determine the interval between surgery and the last day of neoadjuvant CCRT which yields the best tumor response after the short course and long course CCRT. Downstaging was defined as ypT0-2N0M0 and pathologic complete response (ypCR) was defined as ypT0N0M0, respectively.
Results
Both the long and short course groups achieved lowest downstaging rates at < 6 weeks (long 20% vs. short 8%) and highest downstaging rates at 6-7 weeks (long 44% vs. short 40%). The ypCR rates were lowest at < 6 weeks (both long and short 0%) and highest at 6-7 weeks (long 21% vs. short 11%) in both the short and long course arms. The downstaging and ypCR rates of long course group gradually declined after the peak at 6-7 weeks and those of the short course group trend to constantly increase afterwards.
Conclusion
It is optimal to perform surgery at least 6 weeks after both the short course and long course CCRT to obtain maximal tumor regression in locally advanced rectal adenocarcinoma.

Citations

Citations to this article as recorded by  
  • Association between personality types and low anterior resection syndrome in rectal cancer patients following surgery
    Ting‐Yu Chiang, Yu‐Jen Hsu, Yih‐Jong Chern, Chun‐Kai Liao, Wen‐Sy Tsai, Pao‐Shiu Hsieh, Hung‐Chih Hsu, Yu‐Fen Lin, Hsiu‐Lan Lee, Jeng‐Fu You
    Cancer Medicine.2024;[Epub]     CrossRef
  • Lateral Lymph Node Size and Tumor Distance From Anal Verge Accurately Predict Positive Lateral Pelvic Lymph Nodes in Rectal Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Jumyung Song, Ji Hoon Kim, Bong-Hyeon Kye, In Kyu Lee, Hyeon-Min Cho, Yoon Suk Lee
    Diseases of the Colon & Rectum.2023; 66(6): 785.     CrossRef
  • Robotic Lateral Pelvic Lymph Node Dissection Could Harvest More Lateral Pelvic Lymph Nodes over Laparoscopic Approach for Mid-to-Low Rectal Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Jumyung Song, Ri Na Yoo, Ji Hoon Kim, Bong-Hyeon Kye, In Kyu Lee, Hyeon-Min Cho, Yoon Suk Lee
    Biomedicines.2023; 11(6): 1556.     CrossRef
  • Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses
    Miao Yu, Deng-Chao Wang, Sheng Li, Li-Yan Huang, Jian Wei
    International Journal of Colorectal Disease.2022; 37(4): 855.     CrossRef
  • Predicting Factors of Complete Pathological Response in Locally Advanced Rectal Cancer
    AmirHossein Latif, Mohammad Shirkhoda, Mohammad Reza Rouhollahi, Saeed Nemati, Seyed Hossein Yahyazadeh, Kazem Zendehdel, Ahmad Reza Soroush, Aidin Yaghoobi Notash
    Middle East Journal of Digestive Diseases.2022; 14(4): 443.     CrossRef
  • Practical recommendation for treatment of patients with colon cancer during covid-19 pandemic
    M. Yu. Fedyanin
    Meditsinskiy sovet = Medical Council.2020; (9): 213.     CrossRef
  • Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer
    É J Ryan, D P O'Sullivan, M E Kelly, A Z Syed, P C Neary, P R O'Connell, D O Kavanagh, D C Winter, J M O'Riordan
    British Journal of Surgery.2019; 106(10): 1298.     CrossRef
  • Preoperative short-course radiotherapy (5 × 5 Gy) with delayed surgery versus preoperative long-course radiotherapy for locally resectable rectal cancer: a meta-analysis
    Wang Qiaoli, Huang Yongping, Xiong Wei, Xu Guoqiang, Ju Yunhe, Liu Qiuyan, Li Cheng, Guo Mengling, Li Jiayi, Xiong Wei, Yang Yi
    International Journal of Colorectal Disease.2019; 34(12): 2171.     CrossRef
  • Comparison of long course and short course preoperative radiotherapy in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis
    Yongjun Yu, Yuwei Li, Chen Xu, Zhao Zhang, Xipeng Zhang
    Revista Española de Enfermedades Digestivas.2018;[Epub]     CrossRef
  • 9,557 View
  • 333 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study
Joo Ho Lee, Eui Kyu Chie, Seung-Yong Jeong, Tae-You Kim, Dae Yong Kim, Tae Hyun Kim, Sun Young Kim, Ji Yeon Baek, Hee Jin Chang, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Sung Hwan Kim, Jong Hoon Lee, Doo Ho Choi, Hee Chul Park, Sung-Bum Kang, Jae-Sung Kim
Cancer Res Treat. 2018;50(2):506-517.   Published online May 24, 2017
DOI: https://doi.org/10.4143/crt.2016.607
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to validate the prognostic influence of treatment response among patients with positive circumferential resection margin for locally advanced rectal cancer.
Materials and Methods
Clinical data of 197 patientswith positive circumferentialresection margin defined as ≤ 2 mm after preoperative chemoradiotherapy followed by total mesorectal excision between 2004 and 2009were collected forthis multicenter validation study. All patients underwent median 50.4Gy radiationwith concurrentfluoropyrimidine based chemotherapy. Treatmentresponse was dichotomized to good response, including treatmentresponse of grade 2 or 3, and poor response, including grade 0 or 1.
Results
After 52 months median follow-up, 5-year overall survival (OS) for good responders and poor responders was 79.1% and 48.4%, respectively (p < 0.001). In multivariate analysis, circumferential resection margin involvement and treatment response were a prognosticator for OS and locoregional recurrence-free survival. In subgroup analysis, good responders with close margin showed significantly better survival outcomes for survival. Good responders with involved margin and poor responders with close margin shared similar results, whereas poorresponderswith involved margin hadworst survival (5-year OS, 81.2%, 57.0%, 50.0%, and 32.4%, respectively; p < 0.001).
Conclusion
Among patients with positive circumferential resection margin after preoperative chemoradiotherapy, survival of the good responders was significantly better than poor responders. Subgroup analysis revealed that definition of positive circumferential resection margin may be individualized as involvement for good responders, whereas ≤ 2 mm for poor responders.

Citations

Citations to this article as recorded by  
  • Tailored Strategy for Locally Advanced Rectal Carcinoma (GRECCAR 4): Long-term Results From a Multicenter, Randomized, Open-Label, Phase II Trial
    Philippe Rouanet, Eric Rullier, Bernard Lelong, Philippe Maingon, Jean-Jacques Tuech, Denis Pezet, Florence Castan, Stephanie Nougaret
    Diseases of the Colon & Rectum.2022; 65(8): 986.     CrossRef
  • Colorectal Cancer Surgery Quality in Manitoba: A Population-Based Descriptive Analysis
    Iresha Ratnayake, Jason Park, Natalie Biswanger, Allison Feely, Grace Musto, Kathleen Decker
    Current Oncology.2021; 28(3): 2239.     CrossRef
  • 11,085 View
  • 266 Download
  • 4 Web of Science
  • 2 Crossref
Close layer
Meta-Analysis
Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis
Kyung Su Kim, Jeanny Kwon, Kyubo Kim, Eui Kyu Chie
Cancer Res Treat. 2017;49(3):824-833.   Published online August 26, 2016
DOI: https://doi.org/10.4143/crt.2016.336
AbstractAbstract PDFPubReaderePub
Purpose
While curative resection is the only chance of cure in pancreatic cancer, controversies exist about the impact of surgical margin status on survival. Non-standardized pathologic report and different criteria on the R1 status made it difficult to implicate adjuvant therapy after resection based on the margin status. We evaluated the influence of resection margins on survival by meta-analysis.
Materials and Methods
We thoroughly searched electronic databases of PubMed, EMBASE, and Cochrane Library. We included studies reporting survival outcomeswith different margin status: involved margin (R0 mm), margin clearance with ≤ 1 mm (R0-1 mm), and margin with > 1 mm (R>1 mm). Hazard ratio (HR) for overall survival was extracted, and a random-effects model was used for pooled analysis.
Results
A total of eight retrospective studies involving 1,932 patients were included. Pooled HR for overall survival showed that patients with R>1 mm had reduced risk of death than those with R0-1 mm (HR, 0.74; 95% confidence interval [CI], 0.61 to 0.88; p=0.001). In addition, patients with R0-1 mm had reduced risk of death than those with R0 mm (HR, 0.81; 95% CI, 0.72 to 0.91; p < 0.001). There was no heterogeneity between the included studies (I 2 index, 42% and 0%; p=0.10 and p=0.82, respectively).
Conclusion
Our results suggest that stratification of the patients based on margin status is warranted in the clinical trials assessing the role of adjuvant treatment for pancreatic cancer.

Citations

Citations to this article as recorded by  
  • Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy
    Ross J. Taylor, Gregory J. Matthews, Robert H. Aseltine, Emma C. Fields
    Brachytherapy.2024; 23(3): 355.     CrossRef
  • Laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) for adenocarcinoma of the body and tail of the pancreas — technical considerations with analysis of surgical outcomes
    Maciej Borys, Michał Wysocki, Krystyna Gałązka, Maciej Stanek, Andrzej Budzyński
    Langenbeck's Archives of Surgery.2024;[Epub]     CrossRef
  • Neoadjuvant treatment for pancreatic cancer: Controversies and advances
    Douglas Dias e Silva, Vincent Chung
    Cancer Treatment and Research Communications.2024; 39: 100804.     CrossRef
  • Stapled Arterial Divestment in Surgery for Locally Advanced Pancreatic Cancer
    Krishna Kotecha, Juanita Chui, Kai Brown, Anubhav Mittal, Jaswinder Samra
    Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?
    Kosuke Kobayashi, Yoshihiro Ono, Shoki Sato, Tomotaka Kato, Atsushi Oba, Takafumi Sato, Hiromichi Ito, Yosuke Inoue, Manabu Takamatsu, Akio Saiura, Yu Takahashi
    Surgery.2023; 173(5): 1220.     CrossRef
  • Rhabdoid carcinoma of the pancreas: A rare cause of unidentified carcinomas of the pancreas
    Ayoub Madani, Anass Derkaoui, Tarik Deflaoui, Hanane El Aggari, Nadir Miry, Benani Amal, Rachid Jabi, Mohamed Bouziane
    Surgery Open Digestive Advance.2023; 9: 100076.     CrossRef
  • Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide study
    Trine Aaquist, Claus W. Fristrup, Jane P. Hasselby, Stephen Hamilton-Dutoit, Mikkel Eld, Per Pfeiffer, Michael B. Mortensen, Sönke Detlefsen
    HPB.2023; 25(7): 826.     CrossRef
  • Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) — Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study
    Vikram Chaudhari, Anant Ramaswamy, Sujay Srinivas, Ajit Agarwal, Ramakrishnan Ayloor Seshadri, Vineet Talwar, Prabhat Bhargava, Shaifali Goel, Smita Kayal, Pradeep Rebala, Bharat Prajapati, Devendra Parikh, Jagdish Kothari, Ramesh M. Ch, Jacob Mathew Kada
    Journal of Gastrointestinal Cancer.2023; 54(4): 1338.     CrossRef
  • Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9
    Dengfeng Li, Qing Peng, Leyao Wang, Wei Cai, Meng Liang, Siyun Liu, Xiaohong Ma, Xinming Zhao
    European Radiology.2023; 34(1): 509.     CrossRef
  • Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria
    Dong Hwan Kim, Bohyun Kim, Dong Jin Chung, Kyung Ah Kim, Su Lim Lee, Moon Hyung Choi, Hokun Kim, Sung Eun Rha
    The British Journal of Radiology.2023;[Epub]     CrossRef
  • Biliary Adverse Events during Neoadjuvant Therapy for Pancreatic Cancer
    Sam Z. Thalji, Deemantha Fernando, Kulwinder S. Dua, Srivats Madhavan, Phillip Chisholm, Zachary L. Smith, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Ben George, Mandana Kamgar, Beth A. Erickson, William A. Hall, Douglas B. Evans, Susa
    Annals of Surgery.2023;[Epub]     CrossRef
  • Lymph Node Stations of Pancreas Which Are Identified in Real Color Sectioned Images of a Cadaver With Pancreatic Cancer
    Chung Yoh Kim, Yongwook Jung, Jin Seo Park
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • CivaSheet intraoperative radiation therapy for pancreatic cancer
    Ross J. Taylor, Dorin Todor, Brian J. Kaplan, Weston Stover, Emma C. Fields
    Brachytherapy.2022; 21(2): 255.     CrossRef
  • Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
    Soomin Ahn, Jong-chan Lee, Jaihwan Kim, Young Hoon Kim, Yoo-Seok Yoon, Ho-Seong Han, Haeryoung Kim, Jin-Hyeok Hwang
    Gut and Liver.2022; 16(1): 129.     CrossRef
  • Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis
    Márton Benke, Nelli Farkas, Péter Hegyi, Benedek Tinusz, Patrícia Sarlós, Bálint Erőss, Kata Szemes, Nóra Vörhendi, Zsolt Szakács, Ákos Szücs
    Pathology and Oncology Research.2022;[Epub]     CrossRef
  • Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis
    Carlo Alberto Pacilio, Elisa Grassi, Andrea Gardini, Francesca Fappiano, Alessandro Passardi, Giovanni Luca Frassineti, Stefano Tamberi, Giorgio Ercolani
    Surgical Practice.2022; 26(3): 155.     CrossRef
  • Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma
    Vincent Dunet, Nermin Halkic, Christine Sempoux, Nicolas Demartines, Michael Montemurro, John O. Prior, Sabine Schmidt
    European Radiology.2021; 31(2): 992.     CrossRef
  • First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer
    Joshua B. Dault, Dorin Todor, Brian J. Kaplan, Jennifer L. Myers, Emma C. Fields
    Brachytherapy.2021; 20(1): 207.     CrossRef
  • Periarterial divestment in pancreatic cancer surgery
    Markus K. Diener, André L. Mihaljevic, Oliver Strobel, Martin Loos, Thomas Schmidt, Martin Schneider, Christoph Berchtold, Arianeb Mehrabi, Beat P. Müller-Stich, Kuirong Jiang, John P. Neoptolemos, Thilo Hackert, Yi Miao, Markus W. Büchler
    Surgery.2021; 169(5): 1019.     CrossRef
  • Advances and challenges of neoadjuvant therapy in pancreatic cancer
    Yang Yu, Peng Zheng, Yajing Chen, Bofang Wang, Maswikiti Ewetse Paul, Pengxian Tao, Dengfeng Wang, Haiyuan Li, Baohong Gu, Lei Gao, Dan Wang, Hao Chen
    Asia-Pacific Journal of Clinical Oncology.2021; 17(6): 425.     CrossRef
  • R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma
    Stefano Crippa, Fabio Giannone, Marco Schiavo Lena, Giulio Belfiori, Stefano Partelli, Domenico Tamburrino, Roberto Delpini, Michele Pagnanelli, Nicolo Pecorelli, Gianpaolo Balzano, Claudio Doglioni, Massimo Falconi
    Annals of Surgical Oncology.2021; 28(8): 4602.     CrossRef
  • Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy
    Ryan K. Schmocker, Daniel Delitto, Michael J. Wright, Ding Ding, John L. Cameron, Kelly J. Lafaro, William R. Burns, Christopher L. Wolfgang, Richard A. Burkhart, Jin He
    Journal of the American College of Surgeons.2021; 232(4): 405.     CrossRef
  • A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications
    Zengyu Feng, Kexian Li, Jianyao Lou, Mindi Ma, Yulian Wu, Chenghong Peng
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Impact of resection margin status on survival in advanced N stage pancreatic cancer – a multi-institutional analysis
    Christian Teske, Richard Stimpel, Marius Distler, Susanne Merkel, Robert Grützmann, Louisa Bolm, Ulrich Wellner, Tobias Keck, Daniela E. Aust, Jürgen Weitz, Thilo Welsch
    Langenbeck's Archives of Surgery.2021; 406(5): 1481.     CrossRef
  • Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study
    Hyung Sun Kim, Tae Ho Hong, Young-Kyoung You, Joon Seong Park, Dong Sup Yoon
    Surgery Today.2021; 51(11): 1775.     CrossRef
  • What do surgeons need to know about the mesopancreas
    Eduardo de Souza M. Fernandes, Oliver Strobel, Camila Girão, Jose Maria A. Moraes-Junior, Orlando Jorge M. Torres
    Langenbeck's Archives of Surgery.2021; 406(8): 2621.     CrossRef
  • Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
    Michail Galanopoulos, Aris Doukatas, Filippos Gkeros, Nikos Viazis, Christos Liatsos
    World Journal of Gastroenterology.2021; 27(24): 3568.     CrossRef
  • Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
    Yinmo Yang, Xueli Bai, Dapeng Bian, Shouwang Cai, Rufu Chen, Feng Cao, Menghua Dai, Chihua Fang, Deliang Fu, Chunlin Ge, Xiaochao Guo, Chunyi Hao, Jihui Hao, Heguang Huang, Zhixiang Jian, Gang Jin, Fei Li, Haimin Li, Shengping Li, Weiqin Li, Yixiong Li, H
    Journal of Pancreatology.2021; 4(2): 49.     CrossRef
  • Paraaortic dissection in “total mesopancreas excision” and “mesopancreas-first resection” pancreaticoduodenectomies for pancreatic cancer: Useless, optional, or necessary?A systematic review
    Nadia Peparini
    Surgical Oncology.2021; 38: 101639.     CrossRef
  • Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy
    Yuki Sunagawa, Masamichi Hayashi, Suguru Yamada, Hiroshi Tanabe, Keisuke Kurimoto, Nobutake Tanaka, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera
    Clinical Epigenetics.2021;[Epub]     CrossRef
  • Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)
    Jae Seung Kang, Lydia Mok, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Yoo-Seok Yoon, Ho-Seong Han, Dae Wook Hwang, Jae Hoon Lee, Woo Jung Lee, Sang Jae Park, Joon Seong Park, Yonghoon Kim, Huisong Lee, Young-Dong Yu, Jae Do Yang, Seung Eun Lee, Il Young
    Gut and Liver.2021; 15(6): 912.     CrossRef
  • Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
    Yugal Limbu, Sujan Regmee, Roshan Ghimire, Dhiresh Kumar Maharjan, Prabin Bikram Thapa
    Cureus.2021;[Epub]     CrossRef
  • Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study
    Marit Kalisvaart, Damian Broadhurst, Francesca Marcon, Rupaly Pande, Andrea Schlegel, Robert Sutcliffe, Ravi Marudanayagam, Darius Mirza, Nikolaos Chatzizacharias, Manuel Abradelo, Paolo Muiesan, John Isaac, Yuk T. Ma, Christopher McConville, Keith Robert
    HPB.2020; 22(9): 1240.     CrossRef
  • Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer
    Stefano Crippa, Giovanni Guarneri, Giulio Belfiori, Stefano Partelli, Michele Pagnanelli, Giulia Gasparini, Gianpaolo Balzano, Marco Schiavo Lena, Corrado Rubini, Claudio Doglioni, Giuseppe Zamboni, Massimo Falconi
    European Journal of Surgical Oncology.2020; 46(8): 1524.     CrossRef
  • Resection or repair of large peripancreatic arteries during robotic pancreatectomy
    Emanuele F. Kauffmann, Niccolò Napoli, Concetta Cacace, Francesca Menonna, Fabio Vistoli, Gabriella Amorese, Ugo Boggi
    Updates in Surgery.2020; 72(1): 145.     CrossRef
  • In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients
    B. Kurlinkus, R. Ahola, E. Zwart, A. Halimi, B. S. Yilmaz, G. O. Ceyhan, J. Laukkarinen
    Scandinavian Journal of Surgery.2020; 109(1): 11.     CrossRef
  • Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition
    Louisa Bolm, Katharina Mueller, Katharina May, Stefan Sondermann, Ekaterina Petrova, Hryhoriy Lapshyn, Kim Christin Honselmann, Dirk Bausch, Sergii Zemskov, Peter Bronsert, Tobias Keck, Steffen Deichmann, Ulrich F. Wellner
    Cancers.2020; 12(4): 882.     CrossRef
  • Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study
    Hongcheng Wang, Jiazhe Liu, Guanggai Xia, Shizhou Lei, Xiuyan Huang, Xinyu Huang
    Scientific Reports.2020;[Epub]     CrossRef
  • Circumferential resection margin (CRM) in pancreatic cancer
    Lena Häberle, Irene Esposito
    Surgery in Practice and Science.2020; 1: 100006.     CrossRef
  • Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
    Tsengelmaa Jamiyan, Takayuki Shiraki, Yoshihiro Kurata, Masanori Ichinose, Keiichi Kubota, Yasuo Imai
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer
    Cosimo Sperti, Alberto Friziero, Simone Serafini, Sergio Bissoli, Alberto Ponzoni, Andrea Grego, Emanuele Grego, Lucia Moletta
    Journal of Clinical Medicine.2020; 9(7): 2169.     CrossRef
  • Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
    Aaron J. Grossberg, Linda C. Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone, Colin D. Weekes, Charles R. Thomas
    CA: A Cancer Journal for Clinicians.2020; 70(5): 375.     CrossRef
  • Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma
    Byoung Hyuck Kim, Kyubo Kim, Jin-Young Jang, Wooil Kwon, Hongbeom Kim, Kyung-Hun Lee, Do-Youn Oh, Haeryoung Kim, Kyung Bun Lee, Eui Kyu Chie
    European Journal of Surgical Oncology.2020; 46(11): 2122.     CrossRef
  • Pre‐operative diabetes mellitus does not worsen survival and post‐operative outcomes in Chinese patients undergoing resection for pancreatic adenocarcinoma
    Adrian H. K. Yu, Albert C. Y. Chan
    Surgical Practice.2020; 24(4): 132.     CrossRef
  • Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer
    Nathan M. Bolton, Adam H. Maerz, Russell E. Brown, Mona Bansal, John S. Bolton, William C. Conway
    HPB.2019; 21(4): 413.     CrossRef
  • The learning curve for a surgeon in robot-assisted laparoscopic pancreaticoduodenectomy: a retrospective study in a high-volume pancreatic center
    Tao Zhang, Zhi-Ming Zhao, Yuan-Xing Gao, Wan Yee Lau, Rong Liu
    Surgical Endoscopy.2019; 33(9): 2927.     CrossRef
  • Selecting chemotherapy for pancreatic cancer: Far away or so close?
    Si Shi, Xianjun Yu
    Seminars in Oncology.2019; 46(1): 39.     CrossRef
  • Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer
    Sung Jun Ma, Gregory M. Hermann, Kavitha M. Prezzano, Lucas M. Serra, Austin J. Iovoli, Anurag K. Singh
    Cancer Medicine.2019; 8(3): 939.     CrossRef
  • Duktales Adenokarzinom des Pankreas
    E. Gallmeier, T. M. Gress
    Der Gastroenterologe.2019; 14(2): 131.     CrossRef
  • Management of pancreatic head adenocarcinoma: From where to where?
    Kemal Dolay, Fatma Umit Malya, Sami Akbulut
    World Journal of Gastrointestinal Surgery.2019; 11(3): 143.     CrossRef
  • Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
    Vincent P. Groot, Georgios Gemenetzis, Alex B. Blair, Roberto J. Rivero-Soto, Jun Yu, Ammar A. Javed, Richard A. Burkhart, Inne H. M. Borel Rinkes, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Christopher L. Wolfgang, Jin He
    Annals of Surgery.2019; 269(6): 1154.     CrossRef
  • A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer
    Babs G. Sibinga Mulder, Shirin Feshtali, Arantza Fariña Sarasqueta, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg, Bert A. Bonsing, J. Sven D. Mieog
    Ultrasound in Medicine & Biology.2019; 45(8): 2019.     CrossRef
  • Microvascular invasion is a major prognostic factor after pancreatico‐duodenectomy for adenocarcinoma
    Fabrizio Panaro, Tarek Kellil, Julie Vendrell, Valentina Sega, Regis Souche, Tullio Piardi, Piera Leon, Christophe Cassinotto, Eric Assenat, Edoardo Rosso, Francis Navarro
    Journal of Surgical Oncology.2019; 120(3): 483.     CrossRef
  • Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer
    Yoonhyeong Byun, Youngmin Han, Jae Seung Kang, Yoo Jin Choi, Hongbeom Kim, Wooil Kwon, Sun‐Whe Kim, Do‐Youn Oh, Sang Hyub Lee, Ji Kon Ryu, Yong‐Tae Kim, Jin‐Young Jang
    Journal of Hepato-Biliary-Pancreatic Sciences.2019; 26(9): 416.     CrossRef
  • Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer
    Lucia Roa-Peña, Cindy V. Leiton, Sruthi Babu, Chun-Hao Pan, Elizabeth A. Vanner, Ali Akalin, Jela Bandovic, Richard A. Moffitt, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
    Scientific Reports.2019;[Epub]     CrossRef
  • Comment on “The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma”
    Niccolo Petrucciani, Laura Antolino, Giovanni Moschetta, Giovanni Ramacciato
    Annals of Surgery.2019; 270(6): e129.     CrossRef
  • Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?
    Rupaly Pandé, Keith J. Roberts
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Duktales Adenokarzinom des Pankreas
    E. Gallmeier, T. M. Gress
    Der Internist.2018; 59(8): 805.     CrossRef
  • Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study
    Do Young Kim, Young Jin Choi, Young Mi Seol, Hyojeong Kim
    The Korean Journal of Pancreas and Biliary Tract.2018; 23(3): 108.     CrossRef
  • Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
    Andrew McGuigan, Paul Kelly, Richard C Turkington, Claire Jones, Helen G Coleman, R Stephen McCain
    World Journal of Gastroenterology.2018; 24(43): 4846.     CrossRef
  • Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer
    Masaru Miyazaki, Hideyuki Yoshitomi, Shigetsugu Takano, Hiroaki Shimizu, Atsushi Kato, Hiroyuki Yoshidome, Katunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Daisuke Suzuki, Nozomu Sakai, Masayuki Ohtuka
    Langenbeck's Archives of Surgery.2017; 402(3): 447.     CrossRef
  • The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study
    Thilo Hackert, Oliver Strobel, Christoph W. Michalski, André L. Mihaljevic, Arianeb Mehrabi, Beat Müller-Stich, Christoph Berchtold, Alexis Ulrich, Markus W. Büchler
    HPB.2017; 19(11): 1001.     CrossRef
  • 12,401 View
  • 388 Download
  • 66 Web of Science
  • 62 Crossref
Close layer
Original Articles
Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution
Byoung Hyuck Kim, Kyubo Kim, Eui Kyu Chie, Jeanny Kwon, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang
Cancer Res Treat. 2017;49(2):473-483.   Published online August 23, 2016
DOI: https://doi.org/10.4143/crt.2016.166
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to evaluate the long-term outcome in patients undergoing pancreaticoduodenectomy (PD) followed by adjuvant chemoradiotherapy for distal cholangiocarcinoma (DCC) in a high-volume center and to identify the prognostic impact of clinicopathologic factors.
Materials and Methods
A total of 132 consecutive patients who met the inclusion criteria were retrieved from the institutional database from January 1995 to September 2009. All patients received adjuvant treatments at a median of 45 days after the surgery. Median follow-up duration was 57 months (range, 6 to 225 months) for all patients and 105 months for survivors (range, 13 to 225 months).
Results
The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 70.7%, 55.7%, 49.4%, and 48.1%, respectively. Univariate analysis revealed poorly differentiated (P/D) tumors and lymph node (LN) metastasis were significantly associated with DMFS and OS. Additionally, preoperative carbohydrate antigen 19-9 level was significantly correlated with DFS, LRRFS, and DMFS. Upon multivariate analysis for OS, P/D tumors (p=0.015) and LN metastasis (p=0.003) were significant prognosticators that predicted inferior OS. Grade 3 or higher late gastrointestinal toxicity occurred in only one patient (0.8%).
Conclusion
Adjuvant chemoradiotherapy after PD for DCC is an effective and tolerable strategy without significant side effects. During long-term follow-up, we found that prognosis of DCC was mainly influenced by histologic differentiation and LN metastasis. For patients with these risk factors, further research should focus on improving adjuvant strategies as well as other treatment approaches.

Citations

Citations to this article as recorded by  
  • Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for distal cholangiocarcinoma: An international multicentre retrospective cohort study
    Peter LZ. Labib, Thomas B. Russell, Jemimah L. Denson, Mark A. Puckett, Fabio Ausania, Elizabeth Pando, Keith J. Roberts, Ambareen Kausar, Vasileios K. Mavroeidis, Ricky H. Bhogal, Gabriele Marangoni, Sarah C. Thomasset, Adam E. Frampton, Duncan R. Spaldi
    European Journal of Surgical Oncology.2024; 50(6): 108353.     CrossRef
  • Liver Transplantation for Cholangiocarcinoma
    Nadine Soliman, Ashton A. Connor, Sudha Kodali, Rafik Mark Ghobrial
    Digestive Disease Interventions.2024; 08(04): 239.     CrossRef
  • Durable Response to Pembrolizumab and Lenvatinib in a Patient with Chemotherapy-refractory Cholangiocarcinoma
    Winn Soe P, Huang Yiwu
    Archives of Cancer Science and Therapy.2024; 8(1): 041.     CrossRef
  • Impact of adjuvant therapy on outcomes after curative‐intent resection for distal cholangiocarcinoma
    Jing‐Jing Hou, Shishir K. Maithel, Sharon M. Weber, George Poultsides, Christopher L. Wolfgang, Ryan C. Fields, Jin He, Charles Scoggins, Kamron Idrees, Perry Shen, Xu‐Feng Zhang, Timothy M. Pawlik
    Journal of Surgical Oncology.2023; 127(4): 607.     CrossRef
  • The short- and long-term outcomes of pancreaticoduodenectomy for distal cholangiocarcinoma
    Pavel Skalicky, Ondrej Urban, Jiri Ehrmann, Hana Svebisova, Dusan Klos, Jana Tesarikova, Cestmir Neoral, Katerina Knapkova, Martin Lovecek
    Biomedical Papers.2022; 166(4): 386.     CrossRef
  • Patterns of Regional Failure after Pancreaticoduodenectomy in Patients with Distal Extrahepatic Cholangiocarcinoma: Suggestion of the Clinical Target Volume for Elective Nodal Irradiation
    W. Jung, Y. Park, K. Kim, H.J. Park, B.H. Kim
    Clinical Oncology.2022; 34(1): e45.     CrossRef
  • Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review
    Mukul Vij, Yogesh Puri, Ashwin Rammohan, Gowripriya G, Rajesh Rajalingam, Ilankumaran Kaliamoorthy, Mohamed Rela
    World Journal of Gastrointestinal Oncology.2022; 14(3): 607.     CrossRef
  • The prognostic value of the lymph node ratio in patients with distal cholangiocarcinoma after curative intended surgery: A single-center retrospective study
    Chaeyung Oh, Hee Joon Kim, Sang Hwa Song, Eun Kyu Park, Young Hoe Hur, Yang Seok Koh, Chol Kyoon Cho
    Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(2): 168.     CrossRef
  • Etiology, Clinical Presentations, and Short-Term Treatment Outcomes of Extrahepatic Obstructive Jaundice in South-Western Uganda
    Charles Newton Odongo, Carlos Cabrera Dreque, David Mutiibwa, Felix Bongomin, Felix Oyania, Mvuyo Maqhawe Sikhondze, Moses Acan, Raymond Atwine, Fred Kirya, Martin Situma
    Clinical and Experimental Gastroenterology.2022; Volume 15: 79.     CrossRef
  • Lymph Node Ratio Nomogram-Based Prognostic Model for Resected Distal Cholangiocarcinoma
    Marc Perez, Carsten Palnaes Hansen, Fernando Burdio, Gianluca Pellino, Adolfo Pisanu, Roberto Salvia, Marcello Di Martino, Mohammad Abu Hilal, Luca Aldrighetti, Benedetto Ielpo
    Journal of the American College of Surgeons.2022; 235(5): 703.     CrossRef
  • Surgical management of biliary malignancy
    T. Peter Kingham, Victoria G. Aveson, Alice C. Wei, Jason A. Castellanos, Peter J. Allen, Daniel P. Nussbaum, Yinin Hu, Michael I. D'Angelica
    Current Problems in Surgery.2021; 58(2): 100854.     CrossRef
  • Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity‐matched National Cancer Database analysis
    Sivesh K. Kamarajah, Filip Bednar, Clifford S. Cho, Hari Nathan
    Cancer.2021; 127(8): 1266.     CrossRef
  • Re-appraising the role of lymph node status in predicting survival in resected distal cholangiocarcinoma – A meta-analysis and systematic review
    Ken Min Chin, Marcello Di Martino, Nicholas Syn, Benedetto Ielpo, Mohammad Abu Hilal, Brian K.P. Goh, Ye Xin Koh, Mikel Prieto
    European Journal of Surgical Oncology.2021; 47(6): 1267.     CrossRef
  • The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis
    Won Ick Chang, Byoung Hyuck Kim, Hyun-Cheol Kang, Kyubo Kim, Kyung-Hun Lee, Do-Youn Oh, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Eui Kyu Chie
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(2): 395.     CrossRef
  • Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas
    V. Sallinen, J. Sirén, H. Mäkisalo, T. E. Lehtimäki, E. Lantto, A. Kokkola, A. Nordin
    Scandinavian Journal of Surgery.2020; 109(3): 219.     CrossRef
  • Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma
    Weiwen Zhou, Liwen Qian, Yi Rong, Qiong Zhou, Jingjing Shan, Ping Li, Liming Shi, Hai Liu, Xiaonan Sun
    Radiotherapy and Oncology.2020; 147: 111.     CrossRef
  • Proposed Modification of Staging for Distal Cholangiocarcinoma Based on the Lymph Node Ratio Using Korean Multicenter Database
    Yunghun You, Yong Chan Shin, Dong Wook Choi, Jin Seok Heo, Sang Hyun Shin, Naru Kim, Kee-Taek Jang, Hongbeom Kim, Chang-Sup Lim, Sun Hee Chang, Kang Min Han, In Woong Han
    Cancers.2020; 12(3): 762.     CrossRef
  • Combined treatment options for resectable common bile duct cancer patients
    A. N. Polyakov, D. V. Podluzhny, Y. I. Patyutko, S. V. Chulkova, A. V. Egorova, I. S. Bazin, M. A. Shorikov, D. Yu. Frantsev, A. Yu. Syskova
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2020; 25(3): 123.     CrossRef
  • The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
    Eleni Gkika, Maria A. Hawkins, Anca-Ligia Grosu, Thomas B. Brunner
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Prognostic Significance of the Lymph Node Ratio in Surgical Patients With Distal Cholangiocarcinoma
    Xiaocheng Li, Huapeng Lin, Yu Sun, Jianping Gong, Huyi Feng, Jingkai Tu
    Journal of Surgical Research.2019; 236: 2.     CrossRef
  • PROGNOSTIC FACTORS FOR RESECTABLE COMMON BILE DUCT CANCER
    A. Yu. Syskova, I. S. Stilidi, A. N. Polyakov
    Research'n Practical Medicine Journal.2019; 6(2): 69.     CrossRef
  • Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma
    Sojun Hoshimoto, Shoichi Hishinuma, Hirofumi Shirakawa, Moriaki Tomikawa, Iwao Ozawa, Yoshiro Ogata
    Oncology.2019; 96(6): 290.     CrossRef
  • Patterns of failure after resection of extrahepatic bile duct cancer: implications for adjuvant radiotherapy indication and treatment volumes
    Hoon Sik Choi, Ki Mun Kang, Bae Kwon Jeong, Hojin Jeong, Yun Hee Lee, In Bong Ha, Tae Gyu Kim, Jin Ho Song
    Radiation Oncology.2018;[Epub]     CrossRef
  • Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort
    Damien Bergeat, Olivier Turrini, Laetitia Courtin-Tanguy, Stéphanie Truant, Benjamin Darnis, Jean Robert Delpero, Jean-Yves Mabrut, Nicolas Regenet, Laurent Sulpice
    Langenbeck's Archives of Surgery.2018; 403(6): 701.     CrossRef
  • 10,630 View
  • 290 Download
  • 22 Web of Science
  • 24 Crossref
Close layer
Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
Younak Choi, Do-Youn Oh, Kyubo Kim, Eui Kyu Chie, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Sung Whan Ha, Yung-Jue Bang
Cancer Res Treat. 2016;48(3):1045-1055.   Published online October 16, 2015
DOI: https://doi.org/10.4143/crt.2015.226
AbstractAbstract PDFPubReaderePub
Purpose
The optimal treatment strategy for locally advanced pancreatic cancer (LAPC), particularly the role of concurrent chemoradiotherapy (CCRT), remains debatable. We compared the clinical outcomes of CCRT and palliative chemotherapy alone (CA) in patients with unresectable LAPC. Materials and Methods Patients with LAPC who were consecutively treated between 2003 and 2010 were included. Resectability was evaluated according to National Comprehensive Cancer Network ver. 1.2012. The clinical outcomes for each treatment group (CCRT vs. CA) were evaluated retrospectively.
Results
Sixty-three patients (58.9%) and 44 patients (41.1%) were treated with CCRT and CA, respectively. The CCRT cohort included patients who were treated with CCRT with or without chemotherapy backbone (CCRT alone, induction chemotherapy-CCRT, CCRT-maintenance chemotherapy, and induction-CCRT-maintenance chemotherapy). Median progression-free survival (PFS) and overall survival (OS) of all patients were 7.2 months and 13.1 months. PFS of the CCRT and CA groups was 9.0 months and 4.4 months, respectively (p=0.020). OS of the CCRT and CA groups was 15.4 months and 9.3 months, respectively (p=0.011). In multivariate analysis, the adjusted hazard ratio of CCRT was 0.536 (p=0.003) for OS and 0.667 (p=0.078) for PFS. Although the pattern of failure was similar in the CCRT and CA groups, the times to both local and distant failure were significantly longer in the CCRT group. Conclusion In patients with unresectable LAPC, those who underwent CCRT during their entire treatment courses had longer OS than patients treated with chemotherapy alone.

Citations

Citations to this article as recorded by  
  • Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study
    Barbara Salas-Salas, Laura Ferrera-Alayon, Alberto Espinosa-Lopez, Maria Luisa Perez-Rodriguez, Antonio Alayón Afonso, Andres Vera-Rosas, Gabriel Garcia-Plaza, Rodolfo Chicas-Sett, Maria Soledad Martinez-Martin, Elisa Salcedo, Andrea Kannemann, Marta Llor
    Cancers.2025; 17(2): 191.     CrossRef
  • Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study
    B. Salas, L. Ferrera-Alayón, A. Espinosa-López, A. Vera-Rosas, E. Salcedo, A. Kannemann, A. Alayon, R. Chicas-Sett, M. LLoret, P.C. Lara
    Clinical and Translational Radiation Oncology.2024; 45: 100753.     CrossRef
  • Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis
    Bi-Yang Cao, Le-Tian Zhang, Chen-Chen Wu, Jing Wang, Lin Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
    Yanfen Zheng, Rui Huang, Wenxue Zou, Chao Liu, Hongxin Niu, Jinbo Yue
    Precision Radiation Oncology.2022; 6(2): 144.     CrossRef
  • Concurrent Nab-paclitaxel and Radiotherapy
    William T. Arscott, Kevin T. Nead, Adham Bear, Sriram Venigalla, Jacob Shabason, John N. Lukens, John P. Plastaras, Andrzej Wojcieszynski, James Metz, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Arturo Loaiza-Bonilla, Jeffrey Drebin, Major K. Lee, Stuti
    American Journal of Clinical Oncology.2021; 44(9): 469.     CrossRef
  • Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
    Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
    Cancer Research and Treatment.2020; 52(1): 149.     CrossRef
  • Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
    Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE
    Suizo.2018; 33(1): 48.     CrossRef
  • Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
    Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe
    Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(7): 342.     CrossRef
  • Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
    Sophie Otter, Irene Chong, Ria Kalaitzaki, Diana Tait
    International Journal of Hepatobiliary and Pancreatic Diseases.2018; 8(1): 1.     CrossRef
  • Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
    Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
    International Journal of Clinical Oncology.2017; 22(6): 1069.     CrossRef
  • Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
    Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma
    Ilhan Karabicak, Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Hisashi Kosaka, Kentaro Inoue, Yoichi Matsui, Masanori Kon
    Journal of Hepato-Biliary-Pancreatic Sciences.2016; 23(12): 750.     CrossRef
  • 12,156 View
  • 137 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
Hyeon Kang Koh, Kyung Hwan Shin, Kyubo Kim, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Eui Kyu Chie, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee, Seock-Ah Im, Sung Whan Ha
Cancer Res Treat. 2016;48(2):483-490.   Published online June 5, 2015
DOI: https://doi.org/10.4143/crt.2015.111
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. Materials and Methods From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome.
Results
The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. Conclusion RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.

Citations

Citations to this article as recorded by  
  • MiR-210 regulates lung adenocarcinoma by targeting HIF-1α
    Guolei Cao, Peiwen Fan, Ronghui Ma, Qinghe Wang, Lili He, Haiwen Niu, Qin Luo
    Heliyon.2023; 9(5): e16079.     CrossRef
  • Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial
    Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
    European Journal of Cancer.2022; 174: 153.     CrossRef
  • Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial
    Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women
    Oluwole Adeyemi Babatunde, Jan M. Eberth, Tisha Felder, Robert Moran, Samantha Truman, James R. Hebert, Jiajia Zhang, Swann Arp Adams
    Journal of Racial and Ethnic Health Disparities.2021; 8(1): 147.     CrossRef
  • How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
    Lu Cao, Cheng Xu, Gang Cai, Wei-Xiang Qi, Rong Cai, Shu-Bei Wang, Dan Ou, Min Li, Kun-Wei Shen, Jia-Yi Chen
    Annals of Surgical Oncology.2021; 28(4): 2155.     CrossRef
  • Saving the Breast Saves the Lives of Breast Cancer Patients
    Mohammad Esmaeil Akbari, Maryam Khayamzadeh, Hamid Reza Mirzaei, Afshin Moradi, Atieh Akbari, Farid Moradian, Neda Khalili
    International Journal of Surgical Oncology.2020; 2020: 1.     CrossRef
  • Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis
    Si-Ye Chen, Yu Tang, Shu-Lian Wang, Yong-Wen Song, Hui Fang, Jian-Yang Wang, Hao Jing, Jiang-Hu Zhang, Guang-Yi Sun, Xu-Ran Zhao, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning Lu, Hua Ren, Zi-Hao Yu, Ye-Xiong Li
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Evaluation of tissue computed tomography number changes and dosimetric shifts after conventional whole-breast irradiation in patients undergoing breast-conserving surgery
    Joo Hwan Lee, Dong Soo Lee, So Hyun Park, Young Kyu Lee, Jeong Soo Kim, Yong Seok Kim
    Tumor Biology.2018; 40(8): 101042831879188.     CrossRef
  • The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
    Marissa C van Maaren, Reini W Bretveld, Jan J Jobsen, Renske K Veenstra, Catharina GM Groothuis-Oudshoorn, Hendrik Struikmans, John H Maduro, Luc JA Strobbe, Philip MP Poortmans, Sabine Siesling
    British Journal of Cancer.2017; 117(2): 179.     CrossRef
  • 11,508 View
  • 126 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):687-697.   Published online June 4, 2015
DOI: https://doi.org/10.4143/crt.2014.320
AbstractAbstract PDFPubReaderePub
Purpose
We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model.
Materials and Methods
The effect of PP2 on radiosensitivity of U251 and T98G cells was investigated using clonogenic assays. The expression of E-cadherin, matrix metalloproteinases 2 (MMP2), Ephrin type-A receptor 2 (EphA2), and vascular endothelial growth factor (VEGF) was measured by Western blotting and an accumulation of γH2AX foci 6 hours after radiotherapy was measured after PP2 treatment. The effect of PP2 on migration, invasion, and vasculogenic mimicry formation (VMF) of U251 cells was evaluated. In an orthotopical brain tumor model with U251 cells, PP2 was injected intraperitoneally with or without oral TMZ before, during and after whole brain radiotherapy. Bioluminescence images were taken to visualize in vivo tumors and immunohistochemical staining of VEGF, CD31, EphA2, and hypoxia-inducible factor 1a was performed.
Results
PP2 increased radiosensitivity of U251 and T98G cells without decreasing survival of normal human astrocytes. Chemoradiotherapy with PP2 and TMZ resulted in increased accumulation of γH2AX foci. PP2 induced overexpression of E-cadherin and suppression of MMP2, VEGF, and EphA2. PP2 also compromised invasion, migration, and VMF of U251 cells. In brain tumors, chemoradiotherapy with PP2 and TMZ decreased tumor volume best, but not statistically significantly compared with chemoradiotherapy with TMZ. The expression of VEGF and CD31 was suppressed in PP2-treated tumors.
Conclusion
PP2 enhances radiosensitivity of malignant glioma cells and suppresses invasion and migration of U251 cells. Chemoradiotherapy with PP2 and TMZ resulted in non-significant tumor volume decrease.

Citations

Citations to this article as recorded by  
  • Dihydroartemisinin inhibits EphA2/PI3K/Akt pathway-mediated malignant behaviors and vasculogenic mimicry in glioma stem cells
    Huangde Fu, Shengtian Wu, Hechun Shen, Kai Luo, Zhongxiang Huang, Nankun Lu, Yaolin Li, Qian Lan, Yishun Xian
    Heliyon.2025; 11(3): e42095.     CrossRef
  • c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial–mesenchymal transition
    SunYoung Lee, Sunjung Park, Jae-Sung Ryu, Jaegu Kang, Ikhee Kim, Sumin Son, Bok-Soon Lee, Chul-Ho Kim, Yeon Soo Kim
    Experimental Biology and Medicine.2023; 248(6): 492.     CrossRef
  • Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings
    Emir Begagić, Ragib Pugonja, Hakija Bečulić, Amila Čeliković, Lejla Tandir Lihić, Samra Kadić Vukas, Lejla Čejvan, Rasim Skomorac, Edin Selimović, Belma Jaganjac, Fatima Juković-Bihorac, Aldin Jusić, Mirza Pojskić
    Brain Sciences.2023; 13(11): 1602.     CrossRef
  • Hemorrhage in brain tumor – An unresolved issue
    Robert P. Ostrowski, Zhaohui He, Emanuela B. Pucko, Ewa Matyja
    Brain Hemorrhages.2022; 3(2): 98.     CrossRef
  • The interactions of CAP and LYN with the insulin signaling transducer CBL play an important role in polycystic ovary syndrome
    Haoran Shen, Xiao Xu, Zhongpeng Fu, Chengjie Xu, Yao Wang
    Metabolism.2022; 131: 155164.     CrossRef
  • Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma
    Guocai Tian, You Fu, Dahe Zhang, Jiang Li, Zhiyuan Zhang, Xi Yang
    Cancer Cell International.2021;[Epub]     CrossRef
  • Intracellular Progesterone Receptor and cSrc Protein Working Together to Regulate the Activity of Proteins Involved in Migration and Invasion of Human Glioblastoma Cells
    Claudia Bello-Alvarez, Aylin Del Moral-Morales, Aliesha González-Arenas, Ignacio Camacho-Arroyo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
    Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
    Cancer Research and Treatment.2021; 53(3): 685.     CrossRef
  • Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
    Raúl Ortiz, Gloria Perazzoli, Laura Cabeza, Cristina Jiménez-Luna, Raquel Luque, Jose Prados, Consolación Melguizo
    Current Neuropharmacology.2021; 19(4): 513.     CrossRef
  • SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines
    Filippo Torrisi, Luigi Minafra, Francesco P. Cammarata, Gaetano Savoca, Marco Calvaruso, Nunzio Vicario, Laura Maccari, Elodie A. Pérès, Hayriye Özçelik, Myriam Bernaudin, Lorenzo Botta, Giorgio Russo, Rosalba Parenti, Samuel Valable
    International Journal of Molecular Sciences.2020; 21(11): 3917.     CrossRef
  • SRC Kinase in Glioblastoma: News from an Old Acquaintance
    Claudia Cirotti, Claudia Contadini, Daniela Barilà
    Cancers.2020; 12(6): 1558.     CrossRef
  • Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice
    Jooyoung Lee, Dong Hyun Jo, Jin Hyoung Kim, Chang Sik Cho, Jiwon Esther Han, Yona Kim, Hyoungwoo Park, Seung Ho Yoo, Young Suk Yu, Hyo Eun Moon, Hye Ran Park, Dong Gyu Kim, Jeong Hun Kim, Sun Ha Paek
    Experimental & Molecular Medicine.2019; 51(4): 1.     CrossRef
  • Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development
    Mitzli X. Velasco, Adam Kosti, Gabriela D.A. Guardia, Marcia C. Santos, Allison Tegge, Mei Qiao, Bruna R.S. Correa, Greco Hernández, Erzsebet Kokovay, Pedro A.F. Galante, Luiz O.F. Penalva
    RNA.2019; 25(7): 768.     CrossRef
  • Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas
    Hao Chang, Jingning Zhang, Zengli Miao, Yasuo Ding, Xing Xu, Xudong Zhao, Peng Xu, Qing Wang, Yuchang Lin
    Cellular and Molecular Neurobiology.2018; 38(2): 421.     CrossRef
  • ZEB1‐mediated vasculogenic mimicry formation associates with epithelial–mesenchymal transition and cancer stem cell phenotypes in prostate cancer
    Hua Wang, Bin Huang, Bai Mou Li, Kai Yuan Cao, Chen Qiang Mo, Shuang Jian Jiang, Jin Cheng Pan, Zong Ren Wang, Huan Yi Lin, Dao Hu Wang, Shao Peng Qiu
    Journal of Cellular and Molecular Medicine.2018; 22(8): 3768.     CrossRef
  • CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair
    Yuzhen Zhou, Li Chu, Qi Wang, Weixing Dai, Xiaozhou Zhang, Jianfeng Chen, Ling Li, Peipei Ding, Long Zhang, Hongyu Gu, Luying Li, Xinyue Lv, Wei Zhang, Danlei Zhou, Pingzhao Zhang, Guoxiang Cai, Kuaile Zhao, Weiguo Hu
    Cell Death & Disease.2018;[Epub]     CrossRef
  • KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
    Michael J. Ciesielski, Yahao Bu, Stephan A. Munich, Paola Teegarden, Michael P. Smolinski, James L. Clements, Johnson Y. N. Lau, David G. Hangauer, Robert A. Fenstermaker
    Journal of Neuro-Oncology.2018; 140(3): 519.     CrossRef
  • The function and mechanism of preactivated thiomers in triggering epithelial tight junctions opening
    Yang Zhang, Shurong Zhou, Feiyang Deng, Xianhui Chen, Xing Wang, Yaoqi Wang, Hua Zhang, Wenbing Dai, Bing He, Qiang Zhang, Xueqing Wang
    European Journal of Pharmaceutics and Biopharmaceutics.2018; 133: 188.     CrossRef
  • The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
    Fei Shi, Jinying Zhang, Hongyu Liu, Liangliang Wu, Hongyu Jiang, Qiyan Wu, Tianyi Liu, Meiqing Lou, Hao Wu
    Oncotarget.2018; 9(1): 706.     CrossRef
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
    Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
    Antioxidants & Redox Signaling.2017; 27(14): 1067.     CrossRef
  • Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression
    Lei Chen, Damin Cong, Yongzhe Li, Dan Wang, Qingsong Li, Shaoshan Hu
    Ultrasonics Sonochemistry.2017;[Epub]     CrossRef
  • Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
    Tosol Yu, Bong Jun Cho, Eun Jung Choi, Ji Min Park, Dan Hyo Kim, In Ah Kim
    Oncotarget.2016; 7(48): 79089.     CrossRef
  • RND3 promotes Snail 1 protein degradation and inhibits glioblastoma cell migration and invasion
    Baohui Liu, Huimin Dong, Xi Lin, Xiangsheng Yang, Xiaojing Yue, Jian Yang, Yuntao Li, Liquan Wu, Xiaonan Zhu, Shenqi Zhang, Daofeng Tian, Junmin Wang, Qiang Cai, Shanping Mao, Qianxue Chen, Jiang Chang
    Oncotarget.2016; 7(50): 82411.     CrossRef
  • 13,559 View
  • 170 Download
  • 25 Web of Science
  • 23 Crossref
Close layer
In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
Eui Kyu Chie, Jin Hee Shin, Jin Ho Kim, Hak Jae Kim, In Ah Kim, Il Han Kim
Cancer Res Treat. 2015;47(3):527-533.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.026
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.
Materials and Methods
Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated.
Results
Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect.
Conclusion

Results
of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.

Citations

Citations to this article as recorded by  
  • Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study
    Peng-Yi Lee, Yu-Ting Wei, Kun-San Clifford Chao, Chin-Nan Chu, Wen-Hui Chung, Ti-Hao Wang*
    Journal of Cancer Research and Therapeutics.2024; 20(2): 555.     CrossRef
  • Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
    Jessica K Sullivan, Paul P Fahey, Kinglsey E Agho, Simon P Hurley, Zhihui Feng, Richard O Day, David Lim
    Neuro-Oncology Practice.2023; 10(1): 13.     CrossRef
  • The function of histone methylation and acetylation regulators in GBM pathophysiology
    Colin McCornack, Timothy Woodiwiss, Angela Hardi, Hiroko Yano, Albert H. Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Antitumor Activity of Non-thermal Atmospheric Pressure Plasma and Synergistic Effects of Hyperthermia
    TETSUO ADACHI
    Thermal Medicine.2022; 38(1): 1.     CrossRef
  • Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
    Joerg Kotzerke, Dorothee Buesser, Anne Naumann, Roswitha Runge, Lisa Huebinger, Andrea Kliewer, Robert Freudenberg, Claudia Brogsitter
    Cancers.2022; 14(10): 2513.     CrossRef
  • Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions
    Tetsuo Adachi
    YAKUGAKU ZASSHI.2021; 141(10): 1185.     CrossRef
  • Ability of plasma-activated acetated Ringer’s solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors
    Tetsuo Adachi, Yumiko Matsuda, Rika Ishii, Tetsuro Kamiya, Hirokazu Hara
    Journal of Clinical Biochemistry and Nutrition.2020; 67(3): 232.     CrossRef
  • Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide
    Yu-Jen Kuo, Yao-Hsu Yang, I-Yun Lee, Pau-Chung Chen, Jen-Tsung Yang, Ting-Chung Wang, Martin Hsiu-Chu Lin, Wei-Hsun Yang, Chun-Yu Cheng, Kuo-Tai Chen, Wei-Chao Huang, Ming-Hsueh Lee
    Medicine.2020; 99(28): e21147.     CrossRef
  • Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
    Rashmi R. Shah, Peter D. Stonier
    Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6.     CrossRef
  • Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
    Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
    Scientific Reports.2017;[Epub]     CrossRef
  • Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment
    Tetsuo Adachi, Ayame Kano, Saho Nonomura, Tetsuro Kamiya, Hirokazu Hara
    Archives of Biochemistry and Biophysics.2016; 606: 120.     CrossRef
  • Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
    Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
    Journal of Clinical Oncology.2016; 34(7): 731.     CrossRef
  • 11,617 View
  • 107 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma
Byoung Hyuck Kim, Kyubo Kim, Eui Kyu Chie, Jin-Young Jang, Sun Whe Kim, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang, Ijin Joo, Sung W. Ha
Cancer Res Treat. 2015;47(2):274-281.   Published online September 12, 2014
DOI: https://doi.org/10.4143/crt.2014.025
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the outcome of adjuvant chemoradiotherapy (CRT) after distal pancreatectomy (DP) in patients with pancreatic adenocarcinoma, and to identify the prognostic factors for these patients.
Materials and Methods
We performed a retrospective review of 62 consecutive patients who underwent curative DP followed by adjuvant CRT between 2000 and 2011. There were 31 men and 31 women, and the median age was 64 years (range, 38 to 80 years). Adjuvant radiotherapy was delivered to the tumor bed and regional lymph nodes with a median dose of 50.4 Gy (range, 40 to 55.8 Gy). All patients received concomitant chemotherapy, and 53 patients (85.5%) also received maintenance chemotherapy. The median follow-up period was 24 months.
Results
Forty patients (64.5%) experienced relapse. Isolated locoregional recurrence developed in 5 patients (8.1%) and distant metastasis in 35 patients (56.5%), of whom 13 had both locoregional recurrence and distant metastasis. The median overall survival (OS) and disease-free survival (DFS) were 37.5 months and 15.4 months, respectively. On multivariate analysis, splenic artery (SA) invasion (p=0.0186) and resection margin (RM) involvement (p=0.0004) were identified as significant adverse prognosticators for DFS. Also, male gender (p=0.0325) and RM involvement (p=0.0007) were associated with a significantly poor OS. Grade 3 or higher hematologic and gastrointestinal toxicities occurred in 22.6% and 4.8% of patients, respectively.
Conclusion
Adjuvant CRT may improve survival after DP for pancreatic body or tail adenocarcinoma. Our results indicated that SA invasion was a significant factor predicting inferior DFS, as was RM involvement. When SA invasion is identified preoperatively, neoadjuvant treatment may be considered.

Citations

Citations to this article as recorded by  
  • Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study
    Dominique Gantois, Théophile Guilbaud, Ugo Scemama, Edouard Girard, Olivier Picaud, Marine Lefevre, Myriam Elgani, Zeinab Hamidou, Vincent Moutardier, Paul Balandraud, Mircea Chirica, Louise Barbier, David Fuks, David Jérémie Birnbaum
    Langenbeck's Archives of Surgery.2022; 407(1): 153.     CrossRef
  • Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer
    Feng Yin, Mohammed Saad, Jingmei Lin, Christopher R Jackson, Bing Ren, Cynthia Lawson, Dipti M Karamchandani, Belen Quereda Bernabeu, Wei Jiang, Teena Dhir, Richard Zheng, Christopher W Schultz, Dongwei Zhang, Courtney L Thomas, Xuchen Zhang, Jinping Lai,
    Gastroenterology Report.2021; 9(2): 139.     CrossRef
  • Meta-analysis of recurrence pattern after resection for pancreatic cancer
    M Tanaka, A L Mihaljevic, P Probst, M Heckler, U Klaiber, U Heger, M W Büchler, T Hackert
    British Journal of Surgery.2019; 106(12): 1590.     CrossRef
  • Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy
    Ningyi Ma, Zheng Wang, Jiandong Zhao, Jiang Long, Jin Xu, Zhigang Ren, Guoliang Jiang
    Medical Science Monitor.2017; 23: 2315.     CrossRef
  • Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer—Population-Based Analysis with Propensity Score Matching
    Yu Jin Lim, Kyubo Kim, Eui Kyu Chie, BoKyong Kim, Sung W. Ha
    Journal of Gastrointestinal Surgery.2015; 19(12): 2183.     CrossRef
  • 11,899 View
  • 92 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma
Jeong Il Yu, Sang Min Yoon, Hee Chul Park, Jong Hoon Kim, Tae Hyun Kim, Joong-Won Park, Jinsil Seong, Ik Jae Lee, Hong Seok Jang, Chul Seung Kay, Chul Yong Kim, Eui Kyu Chie, Jin Hee Kim, Mi-Sook Kim, Young Min Choi
Cancer Res Treat. 2014;46(4):348-357.   Published online July 16, 2014
DOI: https://doi.org/10.4143/crt.2013.142
AbstractAbstract PDFPubReaderePub
Purpose
We previously reported on a staging system and prognostic index (PITH) for portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT) at a single institution. The aim of this study is to validate the PITH staging system using data from patients at other institutions and to compare it with other published staging systems. Materials and Methods A total of 994 HCC patients with PVTT who were treated with RT between 1998 and 2011 by the Korean Radiation Oncology Group were analyzed retrospectively. All patients were staged using the Cancer of the Liver Italian Program (CLIP), Japanese Integrated Staging (JIS), Okuda, and PITH staging systems, and survival data were analyzed. The likelihood ratio, Akaike information criteria (AIC), time-dependent receiver operating characteristics, and prediction error curve analysis were used to determine discriminatory ability for comparison of staging systems. Results The median survival was 9.2 months. Compared with the other staging systems, the PITH score gave the highest values for likelihood ratio and lowest AIC values, demonstrating that PITH may be a better prognostic model. Although the values were not significant and differences were not exceptional, the PITH score showed slightly better performance with respect to time-dependent area under curve and integrated Brier score of prediction error curve. Conclusion The PITH staging system was validated in this multicenter retrospective study and showed better stratification ability in HCC patients with PVTT than other systems.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol
    Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
    BMJ Open.2022; 12(12): e064688.     CrossRef
  • Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
    Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    KLCA Korean Liver Cancer Association, NCC National Cancer Center
    Gut and Liver.2019; 13(3): 227.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2019; 20(7): 1042.     CrossRef
  • Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis
    H. Abdella, M. K. Shaker, Iman Fawzy Montasser, M. Sobhi, H. Aly, A. Sayed, S. Saleh, A. El Dorry
    Indian Journal of Gastroenterology.2018; 37(2): 127.     CrossRef
  • Strategic application of radiotherapy for hepatocellular carcinoma
    Seo Hee Choi, Jinsil Seong
    Clinical and Molecular Hepatology.2018; 24(2): 114.     CrossRef
  • Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2018; 24(28): 3090.     CrossRef
  • Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2016; 22(30): 6851.     CrossRef
  • Radiotherapy for liver tumors
    Florence K Keane, Shyam K Tanguturi, Andrew X Zhu, Laura A Dawson, Theodore S Hong
    Hepatic Oncology.2015; 2(2): 133.     CrossRef
  • New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
    Hyun Young Woo, Jeong Heo
    Clinical and Molecular Hepatology.2015; 21(2): 115.     CrossRef
  • Current management of hepatocellular carcinoma: An Eastern perspective
    Hyung Joon Yim
    World Journal of Gastroenterology.2015; 21(13): 3826.     CrossRef
  • Portal vein thrombosis: What is new?
    María del Carmen Manzano-Robleda, Beatriz Barranco-Fragoso, Misael Uribe, Nahum Méndez-Sánchez
    Annals of Hepatology.2015; 14(1): 20.     CrossRef
  • 14,064 View
  • 71 Download
  • 12 Web of Science
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP